Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,26763764,elimination half-life,"Pharmacokinetic evaluation showed that 91% of methadone was cleared during this time, with a mean elimination half-life of 59 hours.","Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26763764/),h,59,2269,DB00333,Methadone
,27572136,half-life,"In children, the half-life of R- and S-methadone enantiomers was 34 ± 16 and 24 ± 9 hr, respectively.",Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27572136/),h,34,3706,DB00333,Methadone
,27572136,half-life,"In children, the half-life of R- and S-methadone enantiomers was 34 ± 16 and 24 ± 9 hr, respectively.",Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27572136/),h,24,3707,DB00333,Methadone
,27572136,half-lives,"In adults, R- and S-methadone half-lives were 52 ± 17 and 38 ± 12 hr, respectively.",Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27572136/),h,52,3708,DB00333,Methadone
,27572136,half-lives,"In adults, R- and S-methadone half-lives were 52 ± 17 and 38 ± 12 hr, respectively.",Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27572136/),h,38,3709,DB00333,Methadone
,7205649,volume of distribution,The mean volume of distribution is 7.58 +/- 0.87 liters/kg; the mean elimination T 1/2 is 88.6 +/- 1.9 min and the plasma clearance is 59.3 +/- 1.4 ml/min/kg.,Methadone: radioimmunoassay and pharmacokinetics in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205649/),[l] / [kg],7.58,3860,DB00333,Methadone
,7205649,elimination T 1/2,The mean volume of distribution is 7.58 +/- 0.87 liters/kg; the mean elimination T 1/2 is 88.6 +/- 1.9 min and the plasma clearance is 59.3 +/- 1.4 ml/min/kg.,Methadone: radioimmunoassay and pharmacokinetics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205649/),min,88.6,3861,DB00333,Methadone
,7205649,plasma clearance,The mean volume of distribution is 7.58 +/- 0.87 liters/kg; the mean elimination T 1/2 is 88.6 +/- 1.9 min and the plasma clearance is 59.3 +/- 1.4 ml/min/kg.,Methadone: radioimmunoassay and pharmacokinetics in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205649/),[ml] / [kg·min],59.3,3862,DB00333,Methadone
,7091244,free drug,"At steady state after maternal infusion of the drugs, the maternal: fetal free drug concentration ratios were 7.6 +/- 0.6 for morphine and 2.9 +/- 0.6 for methadone.",A comparison of morphine and methadone disposition in the maternal-fetal unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),,7.6,7006,DB00333,Methadone
,7091244,free drug,"At steady state after maternal infusion of the drugs, the maternal: fetal free drug concentration ratios were 7.6 +/- 0.6 for morphine and 2.9 +/- 0.6 for methadone.",A comparison of morphine and methadone disposition in the maternal-fetal unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),,2.9,7007,DB00333,Methadone
,7091244,concentration ratios,"At steady state after maternal infusion of the drugs, the maternal: fetal free drug concentration ratios were 7.6 +/- 0.6 for morphine and 2.9 +/- 0.6 for methadone.",A comparison of morphine and methadone disposition in the maternal-fetal unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),,7.6,7008,DB00333,Methadone
,7091244,concentration ratios,"At steady state after maternal infusion of the drugs, the maternal: fetal free drug concentration ratios were 7.6 +/- 0.6 for morphine and 2.9 +/- 0.6 for methadone.",A comparison of morphine and methadone disposition in the maternal-fetal unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),,2.9,7009,DB00333,Methadone
,7091244,clearance,The clearance of morphine from mother to fetus (24.9 +/- 3.0 ml/min) was fifteenfold less than that of methadone (390.3 +/- 92.8 ml/min).,A comparison of morphine and methadone disposition in the maternal-fetal unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),[ml] / [min],24.9,7010,DB00333,Methadone
,7091244,clearance,The clearance of morphine from mother to fetus (24.9 +/- 3.0 ml/min) was fifteenfold less than that of methadone (390.3 +/- 92.8 ml/min).,A comparison of morphine and methadone disposition in the maternal-fetal unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),[ml] / [min],390.3,7011,DB00333,Methadone
,7091244,nonplacental clearance,Fetal nonplacental clearance of methadone (381 +/- 89.1 ml/min) was higher than that of morphine (125.6 +/- 15.3 ml/min).,A comparison of morphine and methadone disposition in the maternal-fetal unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),[ml] / [min],381,7012,DB00333,Methadone
,7091244,nonplacental clearance,Fetal nonplacental clearance of methadone (381 +/- 89.1 ml/min) was higher than that of morphine (125.6 +/- 15.3 ml/min).,A comparison of morphine and methadone disposition in the maternal-fetal unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),[ml] / [min],125.6,7013,DB00333,Methadone
,3829576,Varea,The pharmacokinetic parameter estimates reveal rapid and extensive distribution (Varea) and a slow apparent elimination half-life (t1/2) (mean Varea = 3.59 L/kg and harmonic mean t1/2 = 23 hours).,Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829576/),[l] / [kg],3.59,9870,DB00333,Methadone
,3829576,t1/2,The pharmacokinetic parameter estimates reveal rapid and extensive distribution (Varea) and a slow apparent elimination half-life (t1/2) (mean Varea = 3.59 L/kg and harmonic mean t1/2 = 23 hours).,Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829576/),h,23,9871,DB00333,Methadone
,3829576,blood clearance,"The harmonic mean blood clearance is 106 ml/min, the harmonic mean renal clearance is 3.9 ml/min, the mean hepatic extraction ratio is 0.089, and plasma protein binding is 86% to 89%.",Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829576/),[ml] / [min],106,9872,DB00333,Methadone
,3829576,renal clearance,"The harmonic mean blood clearance is 106 ml/min, the harmonic mean renal clearance is 3.9 ml/min, the mean hepatic extraction ratio is 0.089, and plasma protein binding is 86% to 89%.",Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829576/),[ml] / [min],3.9,9873,DB00333,Methadone
,3829576,hepatic extraction ratio,"The harmonic mean blood clearance is 106 ml/min, the harmonic mean renal clearance is 3.9 ml/min, the mean hepatic extraction ratio is 0.089, and plasma protein binding is 86% to 89%.",Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829576/),,0.089,9874,DB00333,Methadone
,3829576,plasma protein binding,"The harmonic mean blood clearance is 106 ml/min, the harmonic mean renal clearance is 3.9 ml/min, the mean hepatic extraction ratio is 0.089, and plasma protein binding is 86% to 89%.",Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829576/),%,86,9875,DB00333,Methadone
,3829576,plasma protein binding,"The harmonic mean blood clearance is 106 ml/min, the harmonic mean renal clearance is 3.9 ml/min, the mean hepatic extraction ratio is 0.089, and plasma protein binding is 86% to 89%.",Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829576/),%,89,9876,DB00333,Methadone
,2303584,Vd,Estimates of Vd (180 +/- 62 L) were not significantly different from those predicted for Vc from body weight using literature values (156 +/- 41).,Pharmacokinetics of continuous intravenous infusion of methadone in the early post-burn period. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303584/),l,180,14306,DB00333,Methadone
,2303584,Vc,Estimates of Vd (180 +/- 62 L) were not significantly different from those predicted for Vc from body weight using literature values (156 +/- 41).,Pharmacokinetics of continuous intravenous infusion of methadone in the early post-burn period. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303584/),,156,14307,DB00333,Methadone
,2303584,Vd,"Estimates of Vd were, however, significantly lower than those predicted for Vz using literature values (282 +/- 74) (P less than 0.001).",Pharmacokinetics of continuous intravenous infusion of methadone in the early post-burn period. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303584/),,282,14308,DB00333,Methadone
,2303584,Vz,"Estimates of Vd were, however, significantly lower than those predicted for Vz using literature values (282 +/- 74) (P less than 0.001).",Pharmacokinetics of continuous intravenous infusion of methadone in the early post-burn period. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303584/),,282,14309,DB00333,Methadone
,2303584,CL,"In addition, CL values (53.0 +/- 19.3 L/h) were significantly higher than those predicted from body weight using literature values (9.2 +/- 2.3 L/h) (P less than 0.001).",Pharmacokinetics of continuous intravenous infusion of methadone in the early post-burn period. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303584/),[l] / [h],53.0,14310,DB00333,Methadone
,2303584,CL,"In addition, CL values (53.0 +/- 19.3 L/h) were significantly higher than those predicted from body weight using literature values (9.2 +/- 2.3 L/h) (P less than 0.001).",Pharmacokinetics of continuous intravenous infusion of methadone in the early post-burn period. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303584/),[l] / [h],9.2,14311,DB00333,Methadone
,2303584,elimination half-life,These changes resulted in estimates of the elimination half-life for methadone of 2.6 +/- 1.1 h.,Pharmacokinetics of continuous intravenous infusion of methadone in the early post-burn period. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303584/),h,2.6,14312,DB00333,Methadone
,11298066,maximum plasma concentration (Cmax),"When combined with efavirenz there was a marked decrease in the maximum plasma concentration (Cmax) of methadone from 689 (range 212-1568) to 358 (range 205-706) ng ml(-1), P = 0.007 : 95% confidence interval (CI) 112-549.",The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298066/),[ng] / [ml],689,14360,DB00333,Methadone
,11298066,maximum plasma concentration (Cmax),"When combined with efavirenz there was a marked decrease in the maximum plasma concentration (Cmax) of methadone from 689 (range 212-1568) to 358 (range 205-706) ng ml(-1), P = 0.007 : 95% confidence interval (CI) 112-549.",The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298066/),[ng] / [ml],358,14361,DB00333,Methadone
,11298066,"area under the methadone concentration curve 0-24 h (AUC(0,24 h))","The mean area under the methadone concentration curve 0-24 h (AUC(0,24 h)) was also significantly reduced from 12341 (range 3682-34147) to 5309 (range 2430-10349) ng ml(-1) h in the presence of efavirenz, P = 0.012 : 95% CI 1921-12143.",The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298066/),[h·ng] / [ml],12341,14362,DB00333,Methadone
,11298066,"area under the methadone concentration curve 0-24 h (AUC(0,24 h))","The mean area under the methadone concentration curve 0-24 h (AUC(0,24 h)) was also significantly reduced from 12341 (range 3682-34147) to 5309 (range 2430-10349) ng ml(-1) h in the presence of efavirenz, P = 0.012 : 95% CI 1921-12143.",The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298066/),[h·ng] / [ml],5309,14363,DB00333,Methadone
,23540608,terminal half-life,"Two goats received methadone (0.2mg/kg) intravenously and the terminal half-life was 88 and 91 min, the volume of distribution 8.4 and 6.1L/kg, and clearance 86 and 123 mL/min/kg.","Methadone in healthy goats - pharmacokinetics, behaviour and blood pressure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23540608/),min,88,19683,DB00333,Methadone
,23540608,terminal half-life,"Two goats received methadone (0.2mg/kg) intravenously and the terminal half-life was 88 and 91 min, the volume of distribution 8.4 and 6.1L/kg, and clearance 86 and 123 mL/min/kg.","Methadone in healthy goats - pharmacokinetics, behaviour and blood pressure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23540608/),min,91,19684,DB00333,Methadone
,23540608,volume of distribution,"Two goats received methadone (0.2mg/kg) intravenously and the terminal half-life was 88 and 91 min, the volume of distribution 8.4 and 6.1L/kg, and clearance 86 and 123 mL/min/kg.","Methadone in healthy goats - pharmacokinetics, behaviour and blood pressure. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23540608/),[l] / [kg],8.4,19685,DB00333,Methadone
,23540608,volume of distribution,"Two goats received methadone (0.2mg/kg) intravenously and the terminal half-life was 88 and 91 min, the volume of distribution 8.4 and 6.1L/kg, and clearance 86 and 123 mL/min/kg.","Methadone in healthy goats - pharmacokinetics, behaviour and blood pressure. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23540608/),[l] / [kg],6.1,19686,DB00333,Methadone
,23540608,clearance,"Two goats received methadone (0.2mg/kg) intravenously and the terminal half-life was 88 and 91 min, the volume of distribution 8.4 and 6.1L/kg, and clearance 86 and 123 mL/min/kg.","Methadone in healthy goats - pharmacokinetics, behaviour and blood pressure. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23540608/),[ml] / [kg·min],86,19687,DB00333,Methadone
,23540608,clearance,"Two goats received methadone (0.2mg/kg) intravenously and the terminal half-life was 88 and 91 min, the volume of distribution 8.4 and 6.1L/kg, and clearance 86 and 123 mL/min/kg.","Methadone in healthy goats - pharmacokinetics, behaviour and blood pressure. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23540608/),[ml] / [kg·min],123,19688,DB00333,Methadone
,23540608,terminal half-life,"After SC administration bioavailability was complete and the terminal half-life was 215 ± 84 min (mean ± SD), Tmax 31 ± 15 min and Cmax 45 ±11 ng/mL.","Methadone in healthy goats - pharmacokinetics, behaviour and blood pressure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23540608/),min,215,19689,DB00333,Methadone
,23540608,Tmax,"After SC administration bioavailability was complete and the terminal half-life was 215 ± 84 min (mean ± SD), Tmax 31 ± 15 min and Cmax 45 ±11 ng/mL.","Methadone in healthy goats - pharmacokinetics, behaviour and blood pressure. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23540608/),min,31,19690,DB00333,Methadone
,23540608,Cmax,"After SC administration bioavailability was complete and the terminal half-life was 215 ± 84 min (mean ± SD), Tmax 31 ± 15 min and Cmax 45 ±11 ng/mL.","Methadone in healthy goats - pharmacokinetics, behaviour and blood pressure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23540608/),[ng] / [ml],45,19691,DB00333,Methadone
,17472504,plasma concentration,"Methadone plasma concentration increased from 2 to 245 ng/mL, and fentanyl plasma concentration decreased from 15 to 8 ng/mL, 25 hours after.",Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472504/),[ng] / [ml],2,24539,DB00333,Methadone
,17472504,plasma concentration,"Methadone plasma concentration increased from 2 to 245 ng/mL, and fentanyl plasma concentration decreased from 15 to 8 ng/mL, 25 hours after.",Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472504/),ng,15,24540,DB00333,Methadone
,427826,primary-phase half-life,Methadone has an average primary-phase half-life of 14.3 hours and a slower secondary-phase half-life averaging 54.8 hours.,Important clinical pharmacologic considerations in the use of methadone in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427826/),h,14.3,25320,DB00333,Methadone
,427826,secondary-phase half-life,Methadone has an average primary-phase half-life of 14.3 hours and a slower secondary-phase half-life averaging 54.8 hours.,Important clinical pharmacologic considerations in the use of methadone in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427826/),h,54.8,25321,DB00333,Methadone
,16167314,LOD,The LOD for all enantiomers is 0.01 microg/mL.,Characterization of the stereoselective biotransformation of ketamine to norketamine via determination of their enantiomers in equine plasma by capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16167314/),[μg] / [ml],0.01,28989,DB00333,Methadone
,6286317,plasma half-lives,"The plasma half-lives in the beta-phase were 19.5 +/- 3.6 h (acidic urine) and 42.1 +/- 8.8h (alkaline urine), respectively (p less than 0.001).",Effect of urinary pH on the disposition of methadone in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286317/),h,19.5,31110,DB00333,Methadone
,6286317,plasma half-lives,"The plasma half-lives in the beta-phase were 19.5 +/- 3.6 h (acidic urine) and 42.1 +/- 8.8h (alkaline urine), respectively (p less than 0.001).",Effect of urinary pH on the disposition of methadone in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286317/),h,42.1,31111,DB00333,Methadone
,6286317,volumes of distribution,"The volumes of distribution were increased when the pretreatment was changed from ammonium chloride to sodium bicarbonate, namely from 3.51 +/- 0.41 l/kg to 5.24 +/- 0.83 l/kg (p less than 0.01).",Effect of urinary pH on the disposition of methadone in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286317/),[l] / [kg],3.51,31112,DB00333,Methadone
,6286317,volumes of distribution,"The volumes of distribution were increased when the pretreatment was changed from ammonium chloride to sodium bicarbonate, namely from 3.51 +/- 0.41 l/kg to 5.24 +/- 0.83 l/kg (p less than 0.01).",Effect of urinary pH on the disposition of methadone in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286317/),[l] / [kg],5.24,31113,DB00333,Methadone
,6286317,body clearance,The body clearance decreased from 134 +/- 21 ml/min (acidic) to 91.9 +/- 9.1 ml/min (alkaline urine) (p less than 0.01).,Effect of urinary pH on the disposition of methadone in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286317/),[ml] / [min],134,31114,DB00333,Methadone
,6286317,body clearance,The body clearance decreased from 134 +/- 21 ml/min (acidic) to 91.9 +/- 9.1 ml/min (alkaline urine) (p less than 0.01).,Effect of urinary pH on the disposition of methadone in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286317/),[ml] / [min],91.9,31115,DB00333,Methadone
,18058416,trough,The mean SU ATV trough was 0.550+/-0.45 microg/mL; the mean NSU ATV trough was 0.780+/-0.590 microg/mL (p > 0.05).,Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058416/),[μg] / [ml],0.550,33570,DB00333,Methadone
,18058416,trough,The mean SU ATV trough was 0.550+/-0.45 microg/mL; the mean NSU ATV trough was 0.780+/-0.590 microg/mL (p > 0.05).,Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058416/),[μg] / [ml],0.780,33571,DB00333,Methadone
,18058416,trough,The mean SU LPV trough was 4.02+/-2.39 microg/mL; the mean NSU LPV trough was 6.67+/-0.910 microg/mL (p = 0.01).,Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058416/),[μg] / [ml],4.02,33572,DB00333,Methadone
,18058416,trough,The mean SU LPV trough was 4.02+/-2.39 microg/mL; the mean NSU LPV trough was 6.67+/-0.910 microg/mL (p = 0.01).,Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058416/),[μg] / [ml],6.67,33573,DB00333,Methadone
,3784573,steady-state plasma concentration,"The steady-state plasma concentration and CSF flux (or appearance rate) of morphine was 0.037 and 0.009 micrograms/min, respectively.",A chronic sheep preparation for the study of drug pharmacokinetics in spinal and ventricular CSF. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784573/),[μg] / [min],0.037,35141,DB00333,Methadone
,3784573,CSF flux,"The steady-state plasma concentration and CSF flux (or appearance rate) of morphine was 0.037 and 0.009 micrograms/min, respectively.",A chronic sheep preparation for the study of drug pharmacokinetics in spinal and ventricular CSF. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784573/),[μg] / [min],0.037,35142,DB00333,Methadone
,3784573,appearance rate,"The steady-state plasma concentration and CSF flux (or appearance rate) of morphine was 0.037 and 0.009 micrograms/min, respectively.",A chronic sheep preparation for the study of drug pharmacokinetics in spinal and ventricular CSF. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784573/),[μg] / [min],0.009,35143,DB00333,Methadone
,25669614,AUC(0-tlast),"The geometric means of the parameters related with the extent of total exposure of levomethadone, i.e., AUC(0-tlast) and AUC(0-∞), were 244.422 ng x h/mL and 332.999 ng x h/mL for test and 246.837 ng x h/mL and 329.467 ngÃh/mL for reference, respectively.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[h·ng] / [ml],244.422,35647,DB00333,Methadone
,25669614,AUC(0-tlast),"The geometric means of the parameters related with the extent of total exposure of levomethadone, i.e., AUC(0-tlast) and AUC(0-∞), were 244.422 ng x h/mL and 332.999 ng x h/mL for test and 246.837 ng x h/mL and 329.467 ngÃh/mL for reference, respectively.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[h·ng] / [ml],246.837,35648,DB00333,Methadone
,25669614,AUC(0-∞),"The geometric means of the parameters related with the extent of total exposure of levomethadone, i.e., AUC(0-tlast) and AUC(0-∞), were 244.422 ng x h/mL and 332.999 ng x h/mL for test and 246.837 ng x h/mL and 329.467 ngÃh/mL for reference, respectively.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[h·ng] / [ml],332.999,35649,DB00333,Methadone
,25669614,AUC(0-∞),"The geometric means of the parameters related with the extent of total exposure of levomethadone, i.e., AUC(0-tlast) and AUC(0-∞), were 244.422 ng x h/mL and 332.999 ng x h/mL for test and 246.837 ng x h/mL and 329.467 ngÃh/mL for reference, respectively.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[ngãh] / [ml],329.467,35650,DB00333,Methadone
,25669614,peak exposure,"The geometric means of the peak exposure for levomethadone, i.e., Cmax, were 8.923 ng/mL for test and 8.635 ng/mL for reference.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[ng] / [ml],8.923,35651,DB00333,Methadone
,25669614,peak exposure,"The geometric means of the peak exposure for levomethadone, i.e., Cmax, were 8.923 ng/mL for test and 8.635 ng/mL for reference.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[ng] / [ml],8.635,35652,DB00333,Methadone
,25669614,Cmax,"The geometric means of the peak exposure for levomethadone, i.e., Cmax, were 8.923 ng/mL for test and 8.635 ng/mL for reference.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[ng] / [ml],8.923,35653,DB00333,Methadone
,25669614,Cmax,"The geometric means of the peak exposure for levomethadone, i.e., Cmax, were 8.923 ng/mL for test and 8.635 ng/mL for reference.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[ng] / [ml],8.635,35654,DB00333,Methadone
,6953740,oral biological availability,"Studies with single doses of methadone have shown that the oral biological availability is 79 +/- 21%, range 41-99%.",Clinical pharmacokinetics of methadone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6953740/),%,79,36108,DB00333,Methadone
,6953740,plasma half-life,"In five subjects treated with ammonium chloride (acidic urine), the plasma half-life of methadone was found to be 19.5 +/- 3.6 h.",Clinical pharmacokinetics of methadone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6953740/),h,19.5,36109,DB00333,Methadone
,6953740,plasma half-lives,When treated with sodium bicarbonate the same subjects had plasma half-lives of 42.1 +/- 8.8 h.,Clinical pharmacokinetics of methadone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6953740/),h,42.1,36110,DB00333,Methadone
,499301,t1/2,The t1/2 of oral methadone-d3 was shorter (22 +/- 2 h) than that of methadone-d0 (52 +/- 20 h).,Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499301/),h,22,39352,DB00333,Methadone
,499301,t1/2,The t1/2 of oral methadone-d3 was shorter (22 +/- 2 h) than that of methadone-d0 (52 +/- 20 h).,Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499301/),h,52,39353,DB00333,Methadone
,30208893,VTI,"The median (range) VTI and VTI*HR were similar at the two time points [11.9(8.1-17.3) vs 13,3(9,4-16,5) cm, and 1172(806-1554) vs 1002(630-1159) cm*bpm, respectively].",Haemodynamic changes during propofol induction in dogs: new findings and approach of monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30208893/),cm,11.9,40762,DB00333,Methadone
,30208893,VTI*HR,"The median (range) VTI and VTI*HR were similar at the two time points [11.9(8.1-17.3) vs 13,3(9,4-16,5) cm, and 1172(806-1554) vs 1002(630-1159) cm*bpm, respectively].",Haemodynamic changes during propofol induction in dogs: new findings and approach of monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30208893/),bpm·cm,1172,40763,DB00333,Methadone
,30208893,VTI*HR,"The median (range) VTI and VTI*HR were similar at the two time points [11.9(8.1-17.3) vs 13,3(9,4-16,5) cm, and 1172(806-1554) vs 1002(630-1159) cm*bpm, respectively].",Haemodynamic changes during propofol induction in dogs: new findings and approach of monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30208893/),bpm·cm,1002,40764,DB00333,Methadone
,15667599,volume of distribution for the central compartment,The volume of distribution for the central compartment was estimated to be 45.7 l and the apparent elimination rate constant of caffeine at 8 hr after inhalation was 0.150 hr(-1) for a typical individual.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),l,45.7,41945,DB00333,Methadone
,15667599,apparent elimination rate constant,The volume of distribution for the central compartment was estimated to be 45.7 l and the apparent elimination rate constant of caffeine at 8 hr after inhalation was 0.150 hr(-1) for a typical individual.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),1/[hr],0.150,41946,DB00333,Methadone
,15667599,bioavailability,The bioavailability was approximately 60%.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),%,60,41947,DB00333,Methadone
,15667599,bioavailability,The bioavailability of inhaled caffeine is approximately 60% in experienced smokers.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),%,60,41948,DB00333,Methadone
,20033681,C(min),"The GM [90% confidence interval (CI)] of the atazanavir C(min), C(max), and AUC of patients taking the methadone oral solution at doses of 20-175 mg/day simultaneously with antiretroviral therapy were impaired compared to patients not taking methadone oral solution: C(min) = 315 (range 197-448) vs. 519 (279-793) ng/mL [GM ratio (GMR) = 0.61, p = 0.229]; C(max) = 1714 (1238-2262) vs. 3190 (2412-4076) ng/mL (GMR = 0.54, p = 0.018); AUC = 21,987 (15,870-29,327) vs. 35,572 (26,211-46,728) ng h/mL (GMR = 0.62, p = 0.074).",Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20033681/),[ng] / [ml],315,43946,DB00333,Methadone
,20033681,C(min),"The GM [90% confidence interval (CI)] of the atazanavir C(min), C(max), and AUC of patients taking the methadone oral solution at doses of 20-175 mg/day simultaneously with antiretroviral therapy were impaired compared to patients not taking methadone oral solution: C(min) = 315 (range 197-448) vs. 519 (279-793) ng/mL [GM ratio (GMR) = 0.61, p = 0.229]; C(max) = 1714 (1238-2262) vs. 3190 (2412-4076) ng/mL (GMR = 0.54, p = 0.018); AUC = 21,987 (15,870-29,327) vs. 35,572 (26,211-46,728) ng h/mL (GMR = 0.62, p = 0.074).",Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20033681/),[ng] / [ml],519,43947,DB00333,Methadone
,20033681,C(max),"The GM [90% confidence interval (CI)] of the atazanavir C(min), C(max), and AUC of patients taking the methadone oral solution at doses of 20-175 mg/day simultaneously with antiretroviral therapy were impaired compared to patients not taking methadone oral solution: C(min) = 315 (range 197-448) vs. 519 (279-793) ng/mL [GM ratio (GMR) = 0.61, p = 0.229]; C(max) = 1714 (1238-2262) vs. 3190 (2412-4076) ng/mL (GMR = 0.54, p = 0.018); AUC = 21,987 (15,870-29,327) vs. 35,572 (26,211-46,728) ng h/mL (GMR = 0.62, p = 0.074).",Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20033681/),[ng] / [ml],1714,43948,DB00333,Methadone
,20033681,C(max),"The GM [90% confidence interval (CI)] of the atazanavir C(min), C(max), and AUC of patients taking the methadone oral solution at doses of 20-175 mg/day simultaneously with antiretroviral therapy were impaired compared to patients not taking methadone oral solution: C(min) = 315 (range 197-448) vs. 519 (279-793) ng/mL [GM ratio (GMR) = 0.61, p = 0.229]; C(max) = 1714 (1238-2262) vs. 3190 (2412-4076) ng/mL (GMR = 0.54, p = 0.018); AUC = 21,987 (15,870-29,327) vs. 35,572 (26,211-46,728) ng h/mL (GMR = 0.62, p = 0.074).",Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20033681/),[ng] / [ml],3190,43949,DB00333,Methadone
,20033681,AUC,"The GM [90% confidence interval (CI)] of the atazanavir C(min), C(max), and AUC of patients taking the methadone oral solution at doses of 20-175 mg/day simultaneously with antiretroviral therapy were impaired compared to patients not taking methadone oral solution: C(min) = 315 (range 197-448) vs. 519 (279-793) ng/mL [GM ratio (GMR) = 0.61, p = 0.229]; C(max) = 1714 (1238-2262) vs. 3190 (2412-4076) ng/mL (GMR = 0.54, p = 0.018); AUC = 21,987 (15,870-29,327) vs. 35,572 (26,211-46,728) ng h/mL (GMR = 0.62, p = 0.074).",Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20033681/),[h·ng] / [ml],"21,987",43950,DB00333,Methadone
,20033681,AUC,"The GM [90% confidence interval (CI)] of the atazanavir C(min), C(max), and AUC of patients taking the methadone oral solution at doses of 20-175 mg/day simultaneously with antiretroviral therapy were impaired compared to patients not taking methadone oral solution: C(min) = 315 (range 197-448) vs. 519 (279-793) ng/mL [GM ratio (GMR) = 0.61, p = 0.229]; C(max) = 1714 (1238-2262) vs. 3190 (2412-4076) ng/mL (GMR = 0.54, p = 0.018); AUC = 21,987 (15,870-29,327) vs. 35,572 (26,211-46,728) ng h/mL (GMR = 0.62, p = 0.074).",Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20033681/),[h·ng] / [ml],"35,572",43951,DB00333,Methadone
,17159797,rate,"The rate of R/S methadone (1.38 in serum, 2.43 in urine) and R/S EDDP (0.83 in urine) confirmed stereoselectivity in methadone metabolism with high individual variability.",Stereoselective determination of methadone and its main metabolite in serum and urine from methadone maintenance patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159797/),,1,46356,DB00333,Methadone
,17159797,rate,"The rate of R/S methadone (1.38 in serum, 2.43 in urine) and R/S EDDP (0.83 in urine) confirmed stereoselectivity in methadone metabolism with high individual variability.",Stereoselective determination of methadone and its main metabolite in serum and urine from methadone maintenance patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159797/),,2.,46357,DB00333,Methadone
,16536895,Steady-state release,Steady-state release in-vitro was 0.5 mg/implant/day.,In-vitro and in-vivo characterization of a buprenorphine delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16536895/),-1·mg,0.5,49365,DB00333,Methadone
,16536895,release rate,"Steady-state plasma levels were attained between 3 and 8 weeks, and were maintained for study duration, with a calculated mean release rate of 0.14+/-0.04 mg/implant/day.",In-vitro and in-vivo characterization of a buprenorphine delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16536895/),[mg] / [d·implant],0.14,49366,DB00333,Methadone
,9742275,plasma concentration ratio,The mean d-methadone:l-methadone plasma concentration ratio was 1.17.,"L-Methadone and D,L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9742275/),,1.17,50693,DB00333,Methadone
,9742275,plasma concentration ratio,"The mean l-methadone:EDDP plasma concentration ratio in the l-methadone group was 22.2 and the d,l-methadone:EDDP plasma concentration ratio was 18.4 .","L-Methadone and D,L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9742275/),,22.2,50694,DB00333,Methadone
,9742275,plasma concentration ratio,"The mean l-methadone:EDDP plasma concentration ratio in the l-methadone group was 22.2 and the d,l-methadone:EDDP plasma concentration ratio was 18.4 .","L-Methadone and D,L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9742275/),,18.4,50695,DB00333,Methadone
,22978825,minimum effective analgesic concentration,The minimum effective analgesic concentration of methadone in opioid naïve adults is 58 mcg · L(-1).,The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978825/),[mcg] / [l],58,54304,DB00333,Methadone
,22978825,central volume (V1),"Population parameter estimates (between-subjects variability) were central volume (V1) 19.1 (126%) L 70 kg(-1), peripheral volumes of distribution V2 65.5 (60%) L 70 kg(-1), V3 485 (23%) L 70 kg(-1), clearance (CL) 9.3 (11%) L · h(-1) · 70 kg(-1), and inter-compartment clearances Q2 282 (95%) L · h(-1) 70 kg(-1), Q3 139 (42%) L · h(-1) 70 kg(-1).",The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978825/),[l] / [70·kg],19.1,54305,DB00333,Methadone
,22978825,peripheral volumes of distribution V2,"Population parameter estimates (between-subjects variability) were central volume (V1) 19.1 (126%) L 70 kg(-1), peripheral volumes of distribution V2 65.5 (60%) L 70 kg(-1), V3 485 (23%) L 70 kg(-1), clearance (CL) 9.3 (11%) L · h(-1) · 70 kg(-1), and inter-compartment clearances Q2 282 (95%) L · h(-1) 70 kg(-1), Q3 139 (42%) L · h(-1) 70 kg(-1).",The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978825/),[l] / [70·kg],65.5,54306,DB00333,Methadone
,22978825,V3,"Population parameter estimates (between-subjects variability) were central volume (V1) 19.1 (126%) L 70 kg(-1), peripheral volumes of distribution V2 65.5 (60%) L 70 kg(-1), V3 485 (23%) L 70 kg(-1), clearance (CL) 9.3 (11%) L · h(-1) · 70 kg(-1), and inter-compartment clearances Q2 282 (95%) L · h(-1) 70 kg(-1), Q3 139 (42%) L · h(-1) 70 kg(-1).",The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978825/),[l] / [70·kg],485,54307,DB00333,Methadone
,22978825,clearance (CL),"Population parameter estimates (between-subjects variability) were central volume (V1) 19.1 (126%) L 70 kg(-1), peripheral volumes of distribution V2 65.5 (60%) L 70 kg(-1), V3 485 (23%) L 70 kg(-1), clearance (CL) 9.3 (11%) L · h(-1) · 70 kg(-1), and inter-compartment clearances Q2 282 (95%) L · h(-1) 70 kg(-1), Q3 139 (42%) L · h(-1) 70 kg(-1).",The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978825/),[l] / [70·h·kg],9.3,54308,DB00333,Methadone
,22978825,inter-compartment clearances,"Population parameter estimates (between-subjects variability) were central volume (V1) 19.1 (126%) L 70 kg(-1), peripheral volumes of distribution V2 65.5 (60%) L 70 kg(-1), V3 485 (23%) L 70 kg(-1), clearance (CL) 9.3 (11%) L · h(-1) · 70 kg(-1), and inter-compartment clearances Q2 282 (95%) L · h(-1) 70 kg(-1), Q3 139 (42%) L · h(-1) 70 kg(-1).",The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978825/),[l] / [70·h·kg],282,54309,DB00333,Methadone
,22978825,Q2,"Population parameter estimates (between-subjects variability) were central volume (V1) 19.1 (126%) L 70 kg(-1), peripheral volumes of distribution V2 65.5 (60%) L 70 kg(-1), V3 485 (23%) L 70 kg(-1), clearance (CL) 9.3 (11%) L · h(-1) · 70 kg(-1), and inter-compartment clearances Q2 282 (95%) L · h(-1) 70 kg(-1), Q3 139 (42%) L · h(-1) 70 kg(-1).",The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978825/),[l] / [70·h·kg],282,54310,DB00333,Methadone
,22978825,Q3,"Population parameter estimates (between-subjects variability) were central volume (V1) 19.1 (126%) L 70 kg(-1), peripheral volumes of distribution V2 65.5 (60%) L 70 kg(-1), V3 485 (23%) L 70 kg(-1), clearance (CL) 9.3 (11%) L · h(-1) · 70 kg(-1), and inter-compartment clearances Q2 282 (95%) L · h(-1) 70 kg(-1), Q3 139 (42%) L · h(-1) 70 kg(-1).",The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978825/),[l] / [70·h·kg],139,54311,DB00333,Methadone
,22978825,terminal elimination half-life,The terminal elimination half-life was 44.4 h.,The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978825/),h,44.4,54312,DB00333,Methadone
<,22978825,observed methadone concentration,The mean observed methadone concentration was <58 mcg · L(-1) by the first hour after administration.,The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978825/),[mcg] / [l],58,54313,DB00333,Methadone
,1588496,AUC,"The serum ZDV levels were significantly higher in the methadone patients, with a 43% increase (p less than 0.05) over the mean AUC of 7.68 microM h observed in the control patients.",Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1588496/),h·μM,7.68,54430,DB00333,Methadone
,11876585,area under the serum concentration-time curve (AUC(0-24h),"No significant differences in the mean area under the serum concentration-time curve (AUC(0-24h); 8,753 +/- 4,280 vs.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),,"8,753",54939,DB00333,Methadone
,11876585,oralclearance(,"8,641 +/- 4,431 microg-h/L),oralclearance(CL/F;9.9 +/- 4.9vs.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),vs,9.9,54940,DB00333,Methadone
,11876585,CL/F,"8,641 +/- 4,431 microg-h/L),oralclearance(CL/F;9.9 +/- 4.9vs.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),vs,9.9,54941,DB00333,Methadone
,11876585,oral volume of distribution (Vd/F,"10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),l,647,54942,DB00333,Methadone
,11876585,oral volume of distribution (Vd/F,"10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),l,481,54943,DB00333,Methadone
,11876585,maximum serum concentration (Cmax,"10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),[μg] / [l],514,54944,DB00333,Methadone
,11876585,maximum serum concentration (Cmax,"10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),[μg] / [l],"5,510",54945,DB00333,Methadone
,11876585,terminal elimination half-life (t 1/2,"10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),h,55.3,54946,DB00333,Methadone
,11876585,terminal elimination half-life (t 1/2,"10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),h,35.0,54947,DB00333,Methadone
,30982709,maximum plasma methadone concentration,"Significantly higher maximum plasma methadone concentration (mean, 25-46 ng mL-1) occurred in all fluconazole-administered treatments than in methadone alone (1.5 ng mL-1).",The effect of fluconazole on oral methadone in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982709/),[ng] / [ml],25-46,55292,DB00333,Methadone
,30982709,maximum plasma methadone concentration,"Significantly higher maximum plasma methadone concentration (mean, 25-46 ng mL-1) occurred in all fluconazole-administered treatments than in methadone alone (1.5 ng mL-1).",The effect of fluconazole on oral methadone in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982709/),[ng] / [ml],1.5,55293,DB00333,Methadone
,30982709,plasma concentration,The mean 12 hour methadone plasma concentration in fluconazole treatments was 11-20 ng mL-1.,The effect of fluconazole on oral methadone in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982709/),[ng] / [ml],11-20,55294,DB00333,Methadone
,27289271,cold pain threshold,"CYP2B6*6 allele carriers had shorter cold pain threshold and pain tolerance times than non-carriers of CYP2B6*6 allele (21.05s vs 33.69s, p=0.036 and 27.15s vs 44.51s, p=0.020, respectively).",Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27289271/),s,21.05,55425,DB00333,Methadone
,27289271,cold pain threshold,"CYP2B6*6 allele carriers had shorter cold pain threshold and pain tolerance times than non-carriers of CYP2B6*6 allele (21.05s vs 33.69s, p=0.036 and 27.15s vs 44.51s, p=0.020, respectively).",Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27289271/),s,33.69,55426,DB00333,Methadone
,27289271,pain tolerance times,"CYP2B6*6 allele carriers had shorter cold pain threshold and pain tolerance times than non-carriers of CYP2B6*6 allele (21.05s vs 33.69s, p=0.036 and 27.15s vs 44.51s, p=0.020, respectively).",Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27289271/),s,33.69,55427,DB00333,Methadone
,27289271,pain tolerance times,"CYP2B6*6 allele carriers had shorter cold pain threshold and pain tolerance times than non-carriers of CYP2B6*6 allele (21.05s vs 33.69s, p=0.036 and 27.15s vs 44.51s, p=0.020, respectively).",Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27289271/),s,27.15,55428,DB00333,Methadone
,27289271,pain tolerance times,"CYP2B6*6 allele carriers had shorter cold pain threshold and pain tolerance times than non-carriers of CYP2B6*6 allele (21.05s vs 33.69s, p=0.036 and 27.15s vs 44.51s, p=0.020, respectively).",Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27289271/),s,44.51,55429,DB00333,Methadone
,27289271,Pain intensity scores,"Pain intensity scores of the CYP2B6*6 allele carriers was 67.55, whereas that of the CYP2B6*6 allele non-carriers was 64.86 (p=0.352).",Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27289271/),,67.55,55430,DB00333,Methadone
,27289271,Pain intensity scores,"Pain intensity scores of the CYP2B6*6 allele carriers was 67.55, whereas that of the CYP2B6*6 allele non-carriers was 64.86 (p=0.352).",Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27289271/),,64.86,55431,DB00333,Methadone
,12405865,bioavailability,Methadone has a mean bioavailability of around 75% (range 36-100%).,Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),%,75,57243,DB00333,Methadone
,12405865,free fraction,"Its mean free fraction is around 13%, with a 4-fold interindividual variation.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),%,13,57244,DB00333,Methadone
,12405865,volume of distribution,Its volume of distribution is about 4 L/kg (range 2-13 L/kg).,Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[l] / [kg],4,57245,DB00333,Methadone
,12405865,Total body clearance,"Total body clearance is about 0.095 L/min, with wide interindividual variation (range 0.02-2 L/min).",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[l] / [min],0.095,57246,DB00333,Methadone
,12405865,elimination half-life,"Plasma concentrations of methadone decrease in a biexponential manner, with a mean value of around 22 hours (range 5-130 hours) for elimination half-life.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),h,22,57247,DB00333,Methadone
,12405865,elimination half-life,"Plasma concentrations of methadone decrease in a biexponential manner, with a mean value of around 22 hours (range 5-130 hours) for elimination half-life.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),h,5,57248,DB00333,Methadone
,12405865,trough plasma concentrations,"In the case of non-response trough plasma concentrations of 400 microg/L for (R,S)-methadone or 250 microg/L for (R)-methadone might be used as target values.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[μg] / [l],400,57249,DB00333,Methadone
,12405865,trough plasma concentrations,"In the case of non-response trough plasma concentrations of 400 microg/L for (R,S)-methadone or 250 microg/L for (R)-methadone might be used as target values.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[μg] / [l],250,57250,DB00333,Methadone
,15588727,transfer,"Also, methadone transfer and its clearance index in the fetal to maternal direction (0.97+/-0.05) was significantly higher (P<0.05) than in the maternal to fetal (0.83+/-0.09).",Bidirectional transfer of methadone across human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15588727/),,0.97,59742,DB00333,Methadone
,15588727,transfer,"Also, methadone transfer and its clearance index in the fetal to maternal direction (0.97+/-0.05) was significantly higher (P<0.05) than in the maternal to fetal (0.83+/-0.09).",Bidirectional transfer of methadone across human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15588727/),,0.83,59743,DB00333,Methadone
,15588727,clearance index,"Also, methadone transfer and its clearance index in the fetal to maternal direction (0.97+/-0.05) was significantly higher (P<0.05) than in the maternal to fetal (0.83+/-0.09).",Bidirectional transfer of methadone across human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15588727/),,0.97,59744,DB00333,Methadone
,15588727,clearance index,"Also, methadone transfer and its clearance index in the fetal to maternal direction (0.97+/-0.05) was significantly higher (P<0.05) than in the maternal to fetal (0.83+/-0.09).",Bidirectional transfer of methadone across human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15588727/),,0.83,59745,DB00333,Methadone
,21348770,R,"The mean (SD) R-, S-, and total methadone M/P ratios were 0.52 (0.28), 0.28 (0.15), and 0.40 (0.21), respectively.",Estimated infant exposure to enantiomer-specific methadone levels in breastmilk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21348770/),,0.52,60080,DB00333,Methadone
,21348770,S-,"The mean (SD) R-, S-, and total methadone M/P ratios were 0.52 (0.28), 0.28 (0.15), and 0.40 (0.21), respectively.",Estimated infant exposure to enantiomer-specific methadone levels in breastmilk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21348770/),,0.28,60081,DB00333,Methadone
,21348770,S-,"The mean (SD) R-, S-, and total methadone M/P ratios were 0.52 (0.28), 0.28 (0.15), and 0.40 (0.21), respectively.",Estimated infant exposure to enantiomer-specific methadone levels in breastmilk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21348770/),,0,60082,DB00333,Methadone
,21348770,RID,"Mean (range) RID of R-, S-, and total methadone were 2.7% (0.7-10.1%), 1.6% (0.3-7.2%), and 2.1% (0.52-8.8%), respectively.",Estimated infant exposure to enantiomer-specific methadone levels in breastmilk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21348770/),,2,60083,DB00333,Methadone
,21348770,RID,"Mean (range) RID of R-, S-, and total methadone were 2.7% (0.7-10.1%), 1.6% (0.3-7.2%), and 2.1% (0.52-8.8%), respectively.",Estimated infant exposure to enantiomer-specific methadone levels in breastmilk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21348770/),,1,60084,DB00333,Methadone
,21348770,RID,"Mean (range) RID of R-, S-, and total methadone were 2.7% (0.7-10.1%), 1.6% (0.3-7.2%), and 2.1% (0.52-8.8%), respectively.",Estimated infant exposure to enantiomer-specific methadone levels in breastmilk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21348770/),,2,60085,DB00333,Methadone
,21492388,C(max),The C(max) of methadone was significantly different (p=0.016) for Phase 1 (5.5 ng mL(-1)) and Phase 2 (171.9 ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[ng] / [ml],5.5,61646,DB00333,Methadone
,21492388,C(max),The C(max) of methadone was significantly different (p=0.016) for Phase 1 (5.5 ng mL(-1)) and Phase 2 (171.9 ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[ng] / [ml],171.9,61647,DB00333,Methadone
,21492388,AUC(0-LAST),The AUC(0-LAST) was also significantly different (p=0.004) for Phase 1 (13.1 hour ng mL(-1)) and Phase 2 (3075.2 hour ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[h·ng] / [ml],13.1,61648,DB00333,Methadone
,21492388,AUC(0-LAST),The AUC(0-LAST) was also significantly different (p=0.004) for Phase 1 (13.1 hour ng mL(-1)) and Phase 2 (3075.2 hour ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[h·ng] / [ml],3075.2,61649,DB00333,Methadone
,19754917,t(1/2),"The mean of the estimated t(1/2) (SD) for each dose (0.1, 0.2 and 0.4 mg/kg) was 2.2 (35.6), 1.3 (46.1) and 1.5 (40.8), and the mean for the estimated C(max) (SD) was 33.9 (6.7), 127.9 (36.0) and 193.5 (65.8) respectively.",Pharmacokinetics of the injectable formulation of methadone hydrochloride administered orally in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754917/),,2.2,61896,DB00333,Methadone
,19754917,t(1/2),"The mean of the estimated t(1/2) (SD) for each dose (0.1, 0.2 and 0.4 mg/kg) was 2.2 (35.6), 1.3 (46.1) and 1.5 (40.8), and the mean for the estimated C(max) (SD) was 33.9 (6.7), 127.9 (36.0) and 193.5 (65.8) respectively.",Pharmacokinetics of the injectable formulation of methadone hydrochloride administered orally in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754917/),,1.3,61897,DB00333,Methadone
,19754917,t(1/2),"The mean of the estimated t(1/2) (SD) for each dose (0.1, 0.2 and 0.4 mg/kg) was 2.2 (35.6), 1.3 (46.1) and 1.5 (40.8), and the mean for the estimated C(max) (SD) was 33.9 (6.7), 127.9 (36.0) and 193.5 (65.8) respectively.",Pharmacokinetics of the injectable formulation of methadone hydrochloride administered orally in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754917/),,1.5,61898,DB00333,Methadone
,19754917,C(max),"The mean of the estimated t(1/2) (SD) for each dose (0.1, 0.2 and 0.4 mg/kg) was 2.2 (35.6), 1.3 (46.1) and 1.5 (40.8), and the mean for the estimated C(max) (SD) was 33.9 (6.7), 127.9 (36.0) and 193.5 (65.8) respectively.",Pharmacokinetics of the injectable formulation of methadone hydrochloride administered orally in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754917/),,33.9,61899,DB00333,Methadone
,19754917,C(max),"The mean of the estimated t(1/2) (SD) for each dose (0.1, 0.2 and 0.4 mg/kg) was 2.2 (35.6), 1.3 (46.1) and 1.5 (40.8), and the mean for the estimated C(max) (SD) was 33.9 (6.7), 127.9 (36.0) and 193.5 (65.8) respectively.",Pharmacokinetics of the injectable formulation of methadone hydrochloride administered orally in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754917/),,127.9,61900,DB00333,Methadone
,19754917,C(max),"The mean of the estimated t(1/2) (SD) for each dose (0.1, 0.2 and 0.4 mg/kg) was 2.2 (35.6), 1.3 (46.1) and 1.5 (40.8), and the mean for the estimated C(max) (SD) was 33.9 (6.7), 127.9 (36.0) and 193.5 (65.8) respectively.",Pharmacokinetics of the injectable formulation of methadone hydrochloride administered orally in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754917/),,193.5,61901,DB00333,Methadone
,8738759,t1/2,"The analgesically active R-methadone has a significantly longer mean elimination half-life than the optical antipode S-methadone (t1/2 = 37.5 and 28.6 h, respectively).",Stereoselective pharmacokinetics of methadone in chronic pain patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738759/),h,37.5,63324,DB00333,Methadone
,8738759,t1/2,"The analgesically active R-methadone has a significantly longer mean elimination half-life than the optical antipode S-methadone (t1/2 = 37.5 and 28.6 h, respectively).",Stereoselective pharmacokinetics of methadone in chronic pain patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738759/),h,28.6,63325,DB00333,Methadone
,8738759,total volume of distribution,The mean total volume of distribution is 496.6 L for R-methadone and 289.1 L for S-methadone.,Stereoselective pharmacokinetics of methadone in chronic pain patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738759/),l,496.6,63326,DB00333,Methadone
,8738759,total volume of distribution,The mean total volume of distribution is 496.6 L for R-methadone and 289.1 L for S-methadone.,Stereoselective pharmacokinetics of methadone in chronic pain patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738759/),l,289.1,63327,DB00333,Methadone
,8738759,clearance,"Significant differences in the mean clearance between R- and S-methadone are seen (0.158 and 0.129 L/min, respectively).",Stereoselective pharmacokinetics of methadone in chronic pain patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738759/),[l] / [min],0.158,63328,DB00333,Methadone
,8738759,clearance,"Significant differences in the mean clearance between R- and S-methadone are seen (0.158 and 0.129 L/min, respectively).",Stereoselective pharmacokinetics of methadone in chronic pain patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738759/),[l] / [min],0.129,63329,DB00333,Methadone
,17224045,concentration,"Initial plasma R,S-methadone concentration was 1,204 ng/ml.",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),ng,"1,204",65499,DB00333,Methadone
,17224045,maximal observed concentrations,"Decrease in plasma R- and S-methadone concentrations was linear and demonstrated a first-order pharmacokinetics (maximal observed concentrations 566 and 637 ng/ml, half-lives 16.1 and 13.2 hours, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),[ng] / [ml],566,65500,DB00333,Methadone
,17224045,maximal observed concentrations,"Decrease in plasma R- and S-methadone concentrations was linear and demonstrated a first-order pharmacokinetics (maximal observed concentrations 566 and 637 ng/ml, half-lives 16.1 and 13.2 hours, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),[ng] / [ml],637,65501,DB00333,Methadone
,17224045,half-lives,"Decrease in plasma R- and S-methadone concentrations was linear and demonstrated a first-order pharmacokinetics (maximal observed concentrations 566 and 637 ng/ml, half-lives 16.1 and 13.2 hours, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),h,16.1,65502,DB00333,Methadone
,17224045,half-lives,"Decrease in plasma R- and S-methadone concentrations was linear and demonstrated a first-order pharmacokinetics (maximal observed concentrations 566 and 637 ng/ml, half-lives 16.1 and 13.2 hours, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),h,13.2,65503,DB00333,Methadone
,17224045,half-maximum effect [EC50],"TK/TD correlation between naloxone infusion rate and R,S- and R-methadone concentrations fitted well a sigmoidal Emax model (concentration associated with a half-maximum effect [EC50] 334 and 173 ng/ml, Hill coefficient 10.0 and 7.8, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),[ng] / [ml],334,65504,DB00333,Methadone
,17224045,half-maximum effect [EC50],"TK/TD correlation between naloxone infusion rate and R,S- and R-methadone concentrations fitted well a sigmoidal Emax model (concentration associated with a half-maximum effect [EC50] 334 and 173 ng/ml, Hill coefficient 10.0 and 7.8, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),[ng] / [ml],173,65505,DB00333,Methadone
,17224045,Hill coefficient,"TK/TD correlation between naloxone infusion rate and R,S- and R-methadone concentrations fitted well a sigmoidal Emax model (concentration associated with a half-maximum effect [EC50] 334 and 173 ng/ml, Hill coefficient 10.0 and 7.8, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),,10.0,65506,DB00333,Methadone
,17224045,Hill coefficient,"TK/TD correlation between naloxone infusion rate and R,S- and R-methadone concentrations fitted well a sigmoidal Emax model (concentration associated with a half-maximum effect [EC50] 334 and 173 ng/ml, Hill coefficient 10.0 and 7.8, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),,7.8,65507,DB00333,Methadone
,22108788,Plasma concentrations,"Plasma concentrations of voriconazole and methadone were high, 12.4 mg/l (therapeutic range: 1-4 mg/l) and 1.6 mg/l (therapeutic range: 0.2-0.4 mg/l), respectively.","Ventricular bigeminy associated with voriconazole, methadone and esomeprazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108788/),[mg] / [l],12.4,66152,DB00333,Methadone
,22108788,Plasma concentrations,"Plasma concentrations of voriconazole and methadone were high, 12.4 mg/l (therapeutic range: 1-4 mg/l) and 1.6 mg/l (therapeutic range: 0.2-0.4 mg/l), respectively.","Ventricular bigeminy associated with voriconazole, methadone and esomeprazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108788/),[mg] / [l],1.6,66153,DB00333,Methadone
,16801002,minimal plasmatic concentration,"In 7 patients who underwent pharmacokinetic studies, the minimal plasmatic concentration of methadone decreased after 4 weeks of nelfinavir treatment from 6.889 ng/ml to 4.354 ng/ml (37%; p = 0.046).",[Clinical and pharmacokinetic interactions between methadone and nelfinavir (Nemesia study)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801002/),[ng] / [ml],6.889,69217,DB00333,Methadone
,16801002,minimal plasmatic concentration,"In 7 patients who underwent pharmacokinetic studies, the minimal plasmatic concentration of methadone decreased after 4 weeks of nelfinavir treatment from 6.889 ng/ml to 4.354 ng/ml (37%; p = 0.046).",[Clinical and pharmacokinetic interactions between methadone and nelfinavir (Nemesia study)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801002/),[ng] / [ml],4.354,69218,DB00333,Methadone
,8894114,Cmax,Omeprazole caused a significant increase in methadone levels (Cmax = 156 +/- 6.5 ng mL-1 against 51 +/- 5.8 ng mL-1 in control; p < 0.05).,The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894114/),[ng] / [ml],156,71943,DB00333,Methadone
,8894114,Cmax,Omeprazole caused a significant increase in methadone levels (Cmax = 156 +/- 6.5 ng mL-1 against 51 +/- 5.8 ng mL-1 in control; p < 0.05).,The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894114/),[ng] / [ml],51,71944,DB00333,Methadone
,8894114,AUC0-180,AUC0-180 was higher (p < 0.05) after omeprazole treatment (18.6 +/- 1.4 micrograms mL-1 min) than in control (6.8 +/- 0.6 microgram mL-1 min).,The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894114/),[min·μg] / [ml],18.6,71945,DB00333,Methadone
,8894114,AUC0-180,AUC0-180 was higher (p < 0.05) after omeprazole treatment (18.6 +/- 1.4 micrograms mL-1 min) than in control (6.8 +/- 0.6 microgram mL-1 min).,The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894114/),[min·μg] / [ml],6.8,71946,DB00333,Methadone
,2485290,half-life,"Estimated half-life for methadone was 8.1 hours, which is much shorter than the usual methadone half-life (greater than 24 hours).",Altered methadone pharmacokinetics in pregnancy: implications for dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2485290/),h,8.1,75432,DB00333,Methadone
greater,2485290,half-life,"Estimated half-life for methadone was 8.1 hours, which is much shorter than the usual methadone half-life (greater than 24 hours).",Altered methadone pharmacokinetics in pregnancy: implications for dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2485290/),h,24,75433,DB00333,Methadone
,16778720,conversion ratio,The mean morphine to methadone conversion ratio was 5.2 with wide interpatient variability (range 1.3 to 11).,Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),,5.2,78944,DB00333,Methadone
,16778720,steady-state concentrations,"Average steady-state concentrations were 197 (98 to 379) mug/L and 272 (55 to 378) mug/L for R- and S-methadone, respectively.",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),[μg] / [l],197,78945,DB00333,Methadone
,16778720,steady-state concentrations,"Average steady-state concentrations were 197 (98 to 379) mug/L and 272 (55 to 378) mug/L for R- and S-methadone, respectively.",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),[μg] / [l],272,78946,DB00333,Methadone
,16778720,apparent volume of distribution,"Mean population pharmacokinetic parameters for a 1-compartment model were 455 L and 338 L for apparent volume of distribution and 53.3 hours and 31.5 hours for half-life for R- and S- methadone, respectively.",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),l,455,78947,DB00333,Methadone
,16778720,apparent volume of distribution,"Mean population pharmacokinetic parameters for a 1-compartment model were 455 L and 338 L for apparent volume of distribution and 53.3 hours and 31.5 hours for half-life for R- and S- methadone, respectively.",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),l,338,78948,DB00333,Methadone
,16778720,half-life,"Mean population pharmacokinetic parameters for a 1-compartment model were 455 L and 338 L for apparent volume of distribution and 53.3 hours and 31.5 hours for half-life for R- and S- methadone, respectively.",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),h,53.3,78949,DB00333,Methadone
,16778720,half-life,"Mean population pharmacokinetic parameters for a 1-compartment model were 455 L and 338 L for apparent volume of distribution and 53.3 hours and 31.5 hours for half-life for R- and S- methadone, respectively.",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),h,31.5,78950,DB00333,Methadone
,16778720,apparent oral clearance,"Bayesian estimates of apparent oral clearance for individual patients were 0.082 (0.052 to 0.112) L/kg/h and 0.117 (0.061 to 0.173) L/kg/h for R- and S- methadone, respectively (mean and 95% confidence interval).",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),[l] / [h·kg],0.082,78951,DB00333,Methadone
,16778720,apparent oral clearance,"Bayesian estimates of apparent oral clearance for individual patients were 0.082 (0.052 to 0.112) L/kg/h and 0.117 (0.061 to 0.173) L/kg/h for R- and S- methadone, respectively (mean and 95% confidence interval).",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),[l] / [h·kg],0.117,78952,DB00333,Methadone
,33481403,peak plasma concentration,"Median total methadone peak plasma concentration was 24.7 (interquartile range [IQR], 19.2-40.8) ng/mL and the median trough was 4.09 (IQR, 2.74-6.4) ng/mL.",A Novel Perioperative Multidose Methadone-Based Multimodal Analgesic Strategy in Children Achieved Safe and Low Analgesic Blood Methadone Levels Enabling Opioid-Sparing Sustained Analgesia With Minimal Adverse Effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33481403/),[ng] / [ml],24.7,81087,DB00333,Methadone
,33481403,trough,"Median total methadone peak plasma concentration was 24.7 (interquartile range [IQR], 19.2-40.8) ng/mL and the median trough was 4.09 (IQR, 2.74-6.4) ng/mL.",A Novel Perioperative Multidose Methadone-Based Multimodal Analgesic Strategy in Children Achieved Safe and Low Analgesic Blood Methadone Levels Enabling Opioid-Sparing Sustained Analgesia With Minimal Adverse Effects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33481403/),[ng] / [ml],4.09,81088,DB00333,Methadone
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,11.3 to 8.4,81404,DB00333,Methadone
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,10.7 to 7.6,81405,DB00333,Methadone
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,12.2 to 8.6,81406,DB00333,Methadone
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,10.6 to 8.6,81407,DB00333,Methadone
,6549062,tmax,"Although the mean peak concentration and the AUC0-8h was significantly lower (p less than 0.01), no marked difference in tmax was observed: 2.8 and 3.1 h respectively.",Preliminary study on the absorption profile after rectal and oral administration of methadone in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6549062/),h,2.8,82385,DB00333,Methadone
,6549062,tmax,"Although the mean peak concentration and the AUC0-8h was significantly lower (p less than 0.01), no marked difference in tmax was observed: 2.8 and 3.1 h respectively.",Preliminary study on the absorption profile after rectal and oral administration of methadone in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6549062/),h,3.1,82386,DB00333,Methadone
,6549062,Rectal absorption conditions,Rectal absorption conditions of methadone from fatty suppositories (3 ml) were found to be less favourable.,Preliminary study on the absorption profile after rectal and oral administration of methadone in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6549062/),ml,3,82387,DB00333,Methadone
,6549062,relative bioavailability,"The peak plasma concentration was only reached 3-4 h after administration, whereas the relative bioavailability up to 8 h after dosing ranged from 35-58%.",Preliminary study on the absorption profile after rectal and oral administration of methadone in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6549062/),%,35-58,82388,DB00333,Methadone
,16433897,Bioavailability (F),Bioavailability (F) of heroin inhalation was estimated as 52% (95% CI 44-61%).,"Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),%,52,85351,DB00333,Methadone
,16433897,Cl/F,"Cl/F was 930 l/hr (95% CI 799-1061 l/hr) after intravenous administration, and 1939 l/hr (95% CI 1661-2217 l/hr) after inhalation.","Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),[l] / [h],930,85352,DB00333,Methadone
,16433897,Cl/F,"Cl/F was 930 l/hr (95% CI 799-1061 l/hr) after intravenous administration, and 1939 l/hr (95% CI 1661-2217 l/hr) after inhalation.","Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),[l] / [h],1939,85353,DB00333,Methadone
,16433897,reaction time,"After heroin administration, the reaction time was significantly prolonged with 28+/-5.3 msec.","Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),ms,28,85354,DB00333,Methadone
,28723731,C/D ratios,The estimated mean methadone C/D ratios was 17.8 nmol·,Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28723731/),nM,17.8,87611,DB00333,Methadone
,28723731,C/D ratios,There was no difference in C/D ratios between heterozygous carriers of CYP2B6*6 (9.1 nmol·L·mg) and noncarriers.,Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28723731/),l·mg·nM,9.1,87612,DB00333,Methadone
,8641323,steady-state plasma concentrations,"The steady-state plasma concentrations of the 20 subjects varied from 65-630 ng x ml(-1) and from 5 to 55 ng x ml(-1), whereas the peak concentrations were 124-1255 ng x ml(-1) and 10-301 ng x ml(-1) for methadone and the AUC(0-24 h) for EDDP varied from 5.9 to 44.6, indicating interindividual differences in metabolic activity.",Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641323/),[ng] / [ml],65-630,92042,DB00333,Methadone
,8641323,steady-state plasma concentrations,"The steady-state plasma concentrations of the 20 subjects varied from 65-630 ng x ml(-1) and from 5 to 55 ng x ml(-1), whereas the peak concentrations were 124-1255 ng x ml(-1) and 10-301 ng x ml(-1) for methadone and the AUC(0-24 h) for EDDP varied from 5.9 to 44.6, indicating interindividual differences in metabolic activity.",Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641323/),[ng] / [ml],5 to 55,92043,DB00333,Methadone
,8641323,peak concentrations,"The steady-state plasma concentrations of the 20 subjects varied from 65-630 ng x ml(-1) and from 5 to 55 ng x ml(-1), whereas the peak concentrations were 124-1255 ng x ml(-1) and 10-301 ng x ml(-1) for methadone and the AUC(0-24 h) for EDDP varied from 5.9 to 44.6, indicating interindividual differences in metabolic activity.",Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641323/),[ng] / [ml],124-1255,92044,DB00333,Methadone
,8641323,peak concentrations,"The steady-state plasma concentrations of the 20 subjects varied from 65-630 ng x ml(-1) and from 5 to 55 ng x ml(-1), whereas the peak concentrations were 124-1255 ng x ml(-1) and 10-301 ng x ml(-1) for methadone and the AUC(0-24 h) for EDDP varied from 5.9 to 44.6, indicating interindividual differences in metabolic activity.",Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641323/),[ng] / [ml],10-301,92045,DB00333,Methadone
,8641323,AUC(0-24 h),"The steady-state plasma concentrations of the 20 subjects varied from 65-630 ng x ml(-1) and from 5 to 55 ng x ml(-1), whereas the peak concentrations were 124-1255 ng x ml(-1) and 10-301 ng x ml(-1) for methadone and the AUC(0-24 h) for EDDP varied from 5.9 to 44.6, indicating interindividual differences in metabolic activity.",Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641323/),,5.9 to 44.6,92046,DB00333,Methadone
,8641323,body clearance,"The mean body clearance was 1.64 ml x min(-1) x kg(-1), whereas the mean elimination rate constant (beta) and plasma half-life (t1/2beta) were 0.026 x h(-1) (range 0.013-0.053 x h(-1)) and 31.2 h (range 13-53 h), respectively.",Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641323/),[ml] / [kg·min],1.64,92047,DB00333,Methadone
,8641323,elimination rate constant (beta),"The mean body clearance was 1.64 ml x min(-1) x kg(-1), whereas the mean elimination rate constant (beta) and plasma half-life (t1/2beta) were 0.026 x h(-1) (range 0.013-0.053 x h(-1)) and 31.2 h (range 13-53 h), respectively.",Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641323/),1/[h],0.026,92048,DB00333,Methadone
,8641323,plasma half-life (t1/2beta),"The mean body clearance was 1.64 ml x min(-1) x kg(-1), whereas the mean elimination rate constant (beta) and plasma half-life (t1/2beta) were 0.026 x h(-1) (range 0.013-0.053 x h(-1)) and 31.2 h (range 13-53 h), respectively.",Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641323/),h,31.2,92049,DB00333,Methadone
,24666686,minimum effective analgesic concentration,"A minimum effective analgesic concentration of methadone in opioid naïve adults is 0.058 mg·l(-1) , while no withdrawal symptoms were observed in neonates suffering opioid withdrawal if plasma concentrations of methadone were above 0.06 mg·l(-1) .","The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666686/),[mg] / [l],0.058,92388,DB00333,Methadone
,24666686,central volume (V1),"Population parameter estimates (between-subject variability) were central volume (V1) 21.5 (29%) l.70 kg(-1) , peripheral volumes of distribution V2 75.1 (23%) l.70 kg(-1) and V3 484 (8%) l.70 kg(-1) , clearance (CL) 9.45 (11%) l·h(-1) .70 kg(-1) , and intercompartment clearances Q2 325 (21%) l·h(-1) .70 kg(-1) and Q3 136 (14%) l·h(-1) .70 kg(-1) .","The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666686/),[l] / [70·kg],21.5,92389,DB00333,Methadone
,24666686,peripheral volumes of distribution V2,"Population parameter estimates (between-subject variability) were central volume (V1) 21.5 (29%) l.70 kg(-1) , peripheral volumes of distribution V2 75.1 (23%) l.70 kg(-1) and V3 484 (8%) l.70 kg(-1) , clearance (CL) 9.45 (11%) l·h(-1) .70 kg(-1) , and intercompartment clearances Q2 325 (21%) l·h(-1) .70 kg(-1) and Q3 136 (14%) l·h(-1) .70 kg(-1) .","The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666686/),[l] / [70·kg],75.1,92390,DB00333,Methadone
,24666686,V3,"Population parameter estimates (between-subject variability) were central volume (V1) 21.5 (29%) l.70 kg(-1) , peripheral volumes of distribution V2 75.1 (23%) l.70 kg(-1) and V3 484 (8%) l.70 kg(-1) , clearance (CL) 9.45 (11%) l·h(-1) .70 kg(-1) , and intercompartment clearances Q2 325 (21%) l·h(-1) .70 kg(-1) and Q3 136 (14%) l·h(-1) .70 kg(-1) .","The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666686/),[l] / [70·kg],484,92391,DB00333,Methadone
,24666686,clearance (CL),"Population parameter estimates (between-subject variability) were central volume (V1) 21.5 (29%) l.70 kg(-1) , peripheral volumes of distribution V2 75.1 (23%) l.70 kg(-1) and V3 484 (8%) l.70 kg(-1) , clearance (CL) 9.45 (11%) l·h(-1) .70 kg(-1) , and intercompartment clearances Q2 325 (21%) l·h(-1) .70 kg(-1) and Q3 136 (14%) l·h(-1) .70 kg(-1) .","The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666686/),[l] / [70·h·kg],9.45,92392,DB00333,Methadone
,24666686,intercompartment clearances Q2,"Population parameter estimates (between-subject variability) were central volume (V1) 21.5 (29%) l.70 kg(-1) , peripheral volumes of distribution V2 75.1 (23%) l.70 kg(-1) and V3 484 (8%) l.70 kg(-1) , clearance (CL) 9.45 (11%) l·h(-1) .70 kg(-1) , and intercompartment clearances Q2 325 (21%) l·h(-1) .70 kg(-1) and Q3 136 (14%) l·h(-1) .70 kg(-1) .","The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666686/),[l] / [70·h·kg],325,92393,DB00333,Methadone
,24666686,Q3,"Population parameter estimates (between-subject variability) were central volume (V1) 21.5 (29%) l.70 kg(-1) , peripheral volumes of distribution V2 75.1 (23%) l.70 kg(-1) and V3 484 (8%) l.70 kg(-1) , clearance (CL) 9.45 (11%) l·h(-1) .70 kg(-1) , and intercompartment clearances Q2 325 (21%) l·h(-1) .70 kg(-1) and Q3 136 (14%) l·h(-1) .70 kg(-1) .","The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666686/),[l] / [70·h·kg],136,92394,DB00333,Methadone
,24666686,formation clearance,"EDDP formation clearance was 9.1 (11%) l·h(-1) .70 kg(-1) , formation clearance of EMDP from EDDP 7.4 (63%) l·h(-1) .70 kg(-1) , elimination clearance of EDDP was 40.9 (26%) l·h(-1) .70 kg(-1) and the rate constant for intermediate compartments 2.17 (43%) h(-1) .","The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666686/),,9.1,92395,DB00333,Methadone
,24666686,formation clearance,"EDDP formation clearance was 9.1 (11%) l·h(-1) .70 kg(-1) , formation clearance of EMDP from EDDP 7.4 (63%) l·h(-1) .70 kg(-1) , elimination clearance of EDDP was 40.9 (26%) l·h(-1) .70 kg(-1) and the rate constant for intermediate compartments 2.17 (43%) h(-1) .","The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666686/),[l] / [70·h·kg],7.4,92396,DB00333,Methadone
,24666686,elimination clearance,"EDDP formation clearance was 9.1 (11%) l·h(-1) .70 kg(-1) , formation clearance of EMDP from EDDP 7.4 (63%) l·h(-1) .70 kg(-1) , elimination clearance of EDDP was 40.9 (26%) l·h(-1) .70 kg(-1) and the rate constant for intermediate compartments 2.17 (43%) h(-1) .","The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666686/),[l] / [70·h·kg],40.9,92397,DB00333,Methadone
,24666686,rate constant for intermediate compartments,"EDDP formation clearance was 9.1 (11%) l·h(-1) .70 kg(-1) , formation clearance of EMDP from EDDP 7.4 (63%) l·h(-1) .70 kg(-1) , elimination clearance of EDDP was 40.9 (26%) l·h(-1) .70 kg(-1) and the rate constant for intermediate compartments 2.17 (43%) h(-1) .","The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666686/),1/[h],2.17,92398,DB00333,Methadone
,24666686,target concentration,A regimen of 0.2 mg·kg(-1) per 8 h in neonates achieves a target concentration of 0.06 mg·l(-1) within 36 h.,"The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666686/),[mg] / [l],0.06,92399,DB00333,Methadone
,34231117,Cmax,"The mean measured daptomycin Cmax and Ctrough were 54.1 μg/mL (CV: 0.32) and 8.7 μg/mL (CV: 0.59), respectively; the mean calculated AUC0-24 was 742.7 μg × h/mL (CV: 0.31).",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[μg] / [ml],54.1,92817,DB00333,Methadone
,34231117,Ctrough,"The mean measured daptomycin Cmax and Ctrough were 54.1 μg/mL (CV: 0.32) and 8.7 μg/mL (CV: 0.59), respectively; the mean calculated AUC0-24 was 742.7 μg × h/mL (CV: 0.31).",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[μg] / [ml],8.7,92818,DB00333,Methadone
,34231117,AUC0-24,"The mean measured daptomycin Cmax and Ctrough were 54.1 μg/mL (CV: 0.32) and 8.7 μg/mL (CV: 0.59), respectively; the mean calculated AUC0-24 was 742.7 μg × h/mL (CV: 0.31).",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[h·μg] / [ml],742.7,92819,DB00333,Methadone
,34231117,"volume of distribution at the steady state (Vd,ss)","The estimated average volume of distribution at the steady state (Vd,ss) and the half-life (t1/2) were 316.5 mL/kg (CV: 0.53) and 14.4 h (CV: 0.30), respectively.",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[ml] / [kg],316.5,92820,DB00333,Methadone
,34231117,half-life (t1/2),"The estimated average volume of distribution at the steady state (Vd,ss) and the half-life (t1/2) were 316.5 mL/kg (CV: 0.53) and 14.4 h (CV: 0.30), respectively.",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),h,14.4,92821,DB00333,Methadone
,34231117,clearance,The mean daptomycin clearance from plasma normalized for body weight (CLwp) was 17.3 mL/(h × kg) (CV: 0.33).,Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[ml] / [h·kg],17.3,92822,DB00333,Methadone
,34231117,Cmax,"The calculated average Cmax and AUC0-24 (183.7 µg/mL and 1277.4 µg × h/mL, respectively) were lower than and statistically significantly different from (p < 0.001 and p = 0.001, respectively) those expected for healthy volunteers.",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[μg] / [ml],183.7,92823,DB00333,Methadone
,34231117,AUC0-24,"The calculated average Cmax and AUC0-24 (183.7 µg/mL and 1277.4 µg × h/mL, respectively) were lower than and statistically significantly different from (p < 0.001 and p = 0.001, respectively) those expected for healthy volunteers.",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[h·μg] / [ml],1277.4,92824,DB00333,Methadone
,21627522,peak concentration,Mean ± SD peak concentration was lower after OTM administration (81.2 ± 14.5 ng/mL) than after IV administration (112.9 ± 28.5 ng/mL).,"Plasma concentrations and behavioral, antinociceptive, and physiologic effects of methadone after intravenous and oral transmucosal administration in cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21627522/),[ng] / [ml],81.2,92834,DB00333,Methadone
,21627522,peak concentration,Mean ± SD peak concentration was lower after OTM administration (81.2 ± 14.5 ng/mL) than after IV administration (112.9 ± 28.5 ng/mL).,"Plasma concentrations and behavioral, antinociceptive, and physiologic effects of methadone after intravenous and oral transmucosal administration in cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21627522/),[ng] / [ml],112.9,92835,DB00333,Methadone
<,30248201,clearance,Drugs with low clearance (<1 mL/[kg·min]) are likely to cause an infant exposure level greater than 10% of the weight-adjusted maternal dose even if the milk-to-plasma concentration ratio is 1.,Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30248201/),[ml] / [kg·min],1,99196,DB00333,Methadone
,30248201,milk-to-plasma concentration ratio,Drugs with low clearance (<1 mL/[kg·min]) are likely to cause an infant exposure level greater than 10% of the weight-adjusted maternal dose even if the milk-to-plasma concentration ratio is 1.,Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30248201/),,1,99197,DB00333,Methadone
,4087182,half-lives,"Plasma-time data showed two sequential half-lives of 8.3 +/- 3.4 (SEM) and 128 +/- 37 min, with apparent dose-independent pharmacokinetics in the studied dose range.",Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),min,8.3,118086,DB00333,Methadone
,4087182,half-lives,"Plasma-time data showed two sequential half-lives of 8.3 +/- 3.4 (SEM) and 128 +/- 37 min, with apparent dose-independent pharmacokinetics in the studied dose range.",Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),min,128,118087,DB00333,Methadone
,4087182,Total body clearances,Total body clearances were 899 +/- 103 (SEM) mL/min.,Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),[ml] / [min],899,118088,DB00333,Methadone
,4087182,Renal clearances,Renal clearances (6-82 mL/min) of methadone were highly variable within and among studies but showed no significant variation with urinary pH or flow rate.,Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),[ml] / [min],6-82,118089,DB00333,Methadone
,4087182,half-lives,The intravenous administration of 2 resulted in two sequential half-lives of 3 and 270 min and no apparent pharmacokinetic dose dependency.,Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),min,3,118090,DB00333,Methadone
,4087182,half-lives,The intravenous administration of 2 resulted in two sequential half-lives of 3 and 270 min and no apparent pharmacokinetic dose dependency.,Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),min,270,118091,DB00333,Methadone
,4087182,Amounts,"Amounts of 2 excreted unchanged in urine and bile were 23% and 5-16% of the dose, respectively.",Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),%,23,118092,DB00333,Methadone
,4087182,Amounts,"Amounts of 2 excreted unchanged in urine and bile were 23% and 5-16% of the dose, respectively.",Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),%,5-16,118093,DB00333,Methadone
,4087182,Renal,Renal and total body clearances were 170 and 1150 mL/min.,Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),[ml] / [min],170,118094,DB00333,Methadone
,4087182,total body clearances,Renal and total body clearances were 170 and 1150 mL/min.,Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),[ml] / [min],1150,118095,DB00333,Methadone
,12134958,area under the effect-time curve (AUCE0-120),"The area under the effect-time curve (AUCE0-120) was (mean +/- interanimal SD) 1859+/-346 min in the females, which was significantly lower than the 4871+/-393 min in the males (P < 0.0001).",Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134958/),min,1859,120773,DB00333,Methadone
,12134958,area under the effect-time curve (AUCE0-120),"The area under the effect-time curve (AUCE0-120) was (mean +/- interanimal SD) 1859+/-346 min in the females, which was significantly lower than the 4871+/-393 min in the males (P < 0.0001).",Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134958/),min,4871,120774,DB00333,Methadone
,12134958,"central volume of distribution, V1","The central volume of distribution, V1, was 1.94+/-0.37 l/kg for female rats and 3.01+/-0.33 l/kg for male rats.",Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134958/),[l] / [kg],1.94,120775,DB00333,Methadone
,12134958,"central volume of distribution, V1","The central volume of distribution, V1, was 1.94+/-0.37 l/kg for female rats and 3.01+/-0.33 l/kg for male rats.",Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134958/),[l] / [kg],3.01,120776,DB00333,Methadone
,12134958,central clearance,"Also, the central clearance was 0.077+/-0.006 l/min/kg and 0.102+/-0.005 l/min/ kg, respectively, for female and male rats.",Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134958/),[l] / [kg·min],0.077,120777,DB00333,Methadone
,12134958,central clearance,"Also, the central clearance was 0.077+/-0.006 l/min/kg and 0.102+/-0.005 l/min/ kg, respectively, for female and male rats.",Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134958/),[l] / [·kg·min],0.102,120778,DB00333,Methadone
,12134958,maximum observed effect parameter (Emax),"The pharmacodynamic maximum observed effect parameter (Emax) was 37%+/-29% in female rats and 85%+/-16% in male rats, and these values were significantly different (P < 0.0001).",Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134958/),%,37,120779,DB00333,Methadone
,12134958,maximum observed effect parameter (Emax),"The pharmacodynamic maximum observed effect parameter (Emax) was 37%+/-29% in female rats and 85%+/-16% in male rats, and these values were significantly different (P < 0.0001).",Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134958/),%,85,120780,DB00333,Methadone
,12134958,concentration eliciting half of Emax (EC50),"The parameter for the concentration eliciting half of Emax (EC50) was 24.1+/-7.5 microg/l in female rats and 20.3+/-2.9 microg/l in male rats, and the Hill-related exponent, gamma, was 6.3+/-3.9 in female rats and 5.5+/-4.1 in male rats.",Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134958/),[μg] / [l],24.1,120781,DB00333,Methadone
,12134958,concentration eliciting half of Emax (EC50),"The parameter for the concentration eliciting half of Emax (EC50) was 24.1+/-7.5 microg/l in female rats and 20.3+/-2.9 microg/l in male rats, and the Hill-related exponent, gamma, was 6.3+/-3.9 in female rats and 5.5+/-4.1 in male rats.",Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134958/),[μg] / [l],20.3,120782,DB00333,Methadone
,12134958,"Hill-related exponent, gamma","The parameter for the concentration eliciting half of Emax (EC50) was 24.1+/-7.5 microg/l in female rats and 20.3+/-2.9 microg/l in male rats, and the Hill-related exponent, gamma, was 6.3+/-3.9 in female rats and 5.5+/-4.1 in male rats.",Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134958/),,6.3,120783,DB00333,Methadone
,12134958,"Hill-related exponent, gamma","The parameter for the concentration eliciting half of Emax (EC50) was 24.1+/-7.5 microg/l in female rats and 20.3+/-2.9 microg/l in male rats, and the Hill-related exponent, gamma, was 6.3+/-3.9 in female rats and 5.5+/-4.1 in male rats.",Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134958/),,5.5,120784,DB00333,Methadone
,19142113,area under the effect versus time curve,"Depressed subjects experienced more dysphoric opioid effects as measured by the Addiction Research Centre Inventory (area under the effect versus time curve, 14 +/- 32 vs -31 +/- 47, P < 0.04) and had higher scores on the Subjective Opioid Withdrawal Scale (area under the effect versus time curve, 33 +/- 97 vs -74 +/- 67, P < 0.02) over the dosage interval.",Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142113/),,14,120875,DB00333,Methadone
,19142113,area under the effect versus time curve,"Depressed subjects experienced more dysphoric opioid effects as measured by the Addiction Research Centre Inventory (area under the effect versus time curve, 14 +/- 32 vs -31 +/- 47, P < 0.04) and had higher scores on the Subjective Opioid Withdrawal Scale (area under the effect versus time curve, 33 +/- 97 vs -74 +/- 67, P < 0.02) over the dosage interval.",Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142113/),,31,120876,DB00333,Methadone
,19142113,area under the effect versus time curve,"Depressed subjects experienced more dysphoric opioid effects as measured by the Addiction Research Centre Inventory (area under the effect versus time curve, 14 +/- 32 vs -31 +/- 47, P < 0.04) and had higher scores on the Subjective Opioid Withdrawal Scale (area under the effect versus time curve, 33 +/- 97 vs -74 +/- 67, P < 0.02) over the dosage interval.",Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142113/),,33,120877,DB00333,Methadone
,19142113,area under the effect versus time curve,"Depressed subjects experienced more dysphoric opioid effects as measured by the Addiction Research Centre Inventory (area under the effect versus time curve, 14 +/- 32 vs -31 +/- 47, P < 0.04) and had higher scores on the Subjective Opioid Withdrawal Scale (area under the effect versus time curve, 33 +/- 97 vs -74 +/- 67, P < 0.02) over the dosage interval.",Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142113/),,74,120878,DB00333,Methadone
,19142113,trough concentration,"Nonholders had significantly higher exposure to unbound (S)-methadone compared with holders, specifically: trough concentration (6.1 +/- 2.7 ng/mL vs 2.7 +/- 1.7 ng/mL, P < 0.01), average steady-state concentration (7.6 +/- 4.0 ng/mL vs 4.1 +/- 2.5 ng/mL, P < 0.05), maximum concentration (14.6 +/- 7.1 ng/mL vs 7.5 +/- 4.2 ng/mL, P < 0.04), and area under the curve (183 +/- 95 h*ng/mL vs 99 +/- 61 h*ng/mL, P < 0.05).",Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142113/),[ng] / [ml],6.1,120879,DB00333,Methadone
,19142113,trough concentration,"Nonholders had significantly higher exposure to unbound (S)-methadone compared with holders, specifically: trough concentration (6.1 +/- 2.7 ng/mL vs 2.7 +/- 1.7 ng/mL, P < 0.01), average steady-state concentration (7.6 +/- 4.0 ng/mL vs 4.1 +/- 2.5 ng/mL, P < 0.05), maximum concentration (14.6 +/- 7.1 ng/mL vs 7.5 +/- 4.2 ng/mL, P < 0.04), and area under the curve (183 +/- 95 h*ng/mL vs 99 +/- 61 h*ng/mL, P < 0.05).",Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142113/),[ng] / [ml],2.7,120880,DB00333,Methadone
,19142113,steady-state concentration,"Nonholders had significantly higher exposure to unbound (S)-methadone compared with holders, specifically: trough concentration (6.1 +/- 2.7 ng/mL vs 2.7 +/- 1.7 ng/mL, P < 0.01), average steady-state concentration (7.6 +/- 4.0 ng/mL vs 4.1 +/- 2.5 ng/mL, P < 0.05), maximum concentration (14.6 +/- 7.1 ng/mL vs 7.5 +/- 4.2 ng/mL, P < 0.04), and area under the curve (183 +/- 95 h*ng/mL vs 99 +/- 61 h*ng/mL, P < 0.05).",Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142113/),[ng] / [ml],7.6,120881,DB00333,Methadone
,19142113,steady-state concentration,"Nonholders had significantly higher exposure to unbound (S)-methadone compared with holders, specifically: trough concentration (6.1 +/- 2.7 ng/mL vs 2.7 +/- 1.7 ng/mL, P < 0.01), average steady-state concentration (7.6 +/- 4.0 ng/mL vs 4.1 +/- 2.5 ng/mL, P < 0.05), maximum concentration (14.6 +/- 7.1 ng/mL vs 7.5 +/- 4.2 ng/mL, P < 0.04), and area under the curve (183 +/- 95 h*ng/mL vs 99 +/- 61 h*ng/mL, P < 0.05).",Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142113/),[ng] / [ml],4.1,120882,DB00333,Methadone
,19142113,maximum concentration,"Nonholders had significantly higher exposure to unbound (S)-methadone compared with holders, specifically: trough concentration (6.1 +/- 2.7 ng/mL vs 2.7 +/- 1.7 ng/mL, P < 0.01), average steady-state concentration (7.6 +/- 4.0 ng/mL vs 4.1 +/- 2.5 ng/mL, P < 0.05), maximum concentration (14.6 +/- 7.1 ng/mL vs 7.5 +/- 4.2 ng/mL, P < 0.04), and area under the curve (183 +/- 95 h*ng/mL vs 99 +/- 61 h*ng/mL, P < 0.05).",Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142113/),[ng] / [ml],14.6,120883,DB00333,Methadone
,19142113,maximum concentration,"Nonholders had significantly higher exposure to unbound (S)-methadone compared with holders, specifically: trough concentration (6.1 +/- 2.7 ng/mL vs 2.7 +/- 1.7 ng/mL, P < 0.01), average steady-state concentration (7.6 +/- 4.0 ng/mL vs 4.1 +/- 2.5 ng/mL, P < 0.05), maximum concentration (14.6 +/- 7.1 ng/mL vs 7.5 +/- 4.2 ng/mL, P < 0.04), and area under the curve (183 +/- 95 h*ng/mL vs 99 +/- 61 h*ng/mL, P < 0.05).",Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142113/),[ng] / [ml],7.5,120884,DB00333,Methadone
,19142113,area under the curve,"Nonholders had significantly higher exposure to unbound (S)-methadone compared with holders, specifically: trough concentration (6.1 +/- 2.7 ng/mL vs 2.7 +/- 1.7 ng/mL, P < 0.01), average steady-state concentration (7.6 +/- 4.0 ng/mL vs 4.1 +/- 2.5 ng/mL, P < 0.05), maximum concentration (14.6 +/- 7.1 ng/mL vs 7.5 +/- 4.2 ng/mL, P < 0.04), and area under the curve (183 +/- 95 h*ng/mL vs 99 +/- 61 h*ng/mL, P < 0.05).",Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142113/),[h·ng] / [ml],183,120885,DB00333,Methadone
,19142113,area under the curve,"Nonholders had significantly higher exposure to unbound (S)-methadone compared with holders, specifically: trough concentration (6.1 +/- 2.7 ng/mL vs 2.7 +/- 1.7 ng/mL, P < 0.01), average steady-state concentration (7.6 +/- 4.0 ng/mL vs 4.1 +/- 2.5 ng/mL, P < 0.05), maximum concentration (14.6 +/- 7.1 ng/mL vs 7.5 +/- 4.2 ng/mL, P < 0.04), and area under the curve (183 +/- 95 h*ng/mL vs 99 +/- 61 h*ng/mL, P < 0.05).",Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19142113/),[h·ng] / [ml],99,120886,DB00333,Methadone
above,1623695,area under the plasma concentration-time curves,Withdrawal symptoms occurred with plasma naloxone area under the plasma concentration-time curves above 550 ng.,Treatment of opioid-induced constipation with oral naloxone: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623695/),ng,550,121859,DB00333,Methadone
≥,33629900,trough methadone concentrations,"Compared with baseline, temperatures significantly decreased for treatment 1 group dogs at 2 to ≥ 4 hours and from 16 to ≥ 50 hours (12 hours after last dose) and for treatment 2 group dogs at 2 to ≥ 36 hours (12 hours after last dose), when trough methadone concentrations were ≥ 21.3 ng/mL.",Multiple-dose pharmacokinetics and opioid effects of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629900/),[ng] / [ml],21.3,123862,DB00333,Methadone
,3839885,peak cisternal CSF morphine concentrations,"The mean peak cisternal CSF morphine concentrations were sustained for 30-40 minutes, and averaged 148 ng/ml, representing 0.3% of the administered dose.","CSF distribution of morphine, methadone and sucrose after intrathecal injection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3839885/),[ng] / [ml],148,124853,DB00333,Methadone
,6653644,Vd beta,The therapeutic failures had a smaller Vd beta and Vdss 3.09 +/- 0.96 1/kg and 2.74 +/- 0.96 1/kg vs 4.56 +/- 1.00 1/kg and 4.20 +/- 0.78 1/kg in the control group.,Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653644/),[1] / [kg],3.09,126610,DB00333,Methadone
,6653644,Vd beta,The therapeutic failures had a smaller Vd beta and Vdss 3.09 +/- 0.96 1/kg and 2.74 +/- 0.96 1/kg vs 4.56 +/- 1.00 1/kg and 4.20 +/- 0.78 1/kg in the control group.,Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653644/),[1] / [kg],4.56,126611,DB00333,Methadone
,6653644,Vdss,The therapeutic failures had a smaller Vd beta and Vdss 3.09 +/- 0.96 1/kg and 2.74 +/- 0.96 1/kg vs 4.56 +/- 1.00 1/kg and 4.20 +/- 0.78 1/kg in the control group.,Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653644/),[1] / [kg],3.09,126612,DB00333,Methadone
,6653644,Vdss,The therapeutic failures had a smaller Vd beta and Vdss 3.09 +/- 0.96 1/kg and 2.74 +/- 0.96 1/kg vs 4.56 +/- 1.00 1/kg and 4.20 +/- 0.78 1/kg in the control group.,Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653644/),[1] / [kg],2.74,126613,DB00333,Methadone
,6653644,Vdss,The therapeutic failures had a smaller Vd beta and Vdss 3.09 +/- 0.96 1/kg and 2.74 +/- 0.96 1/kg vs 4.56 +/- 1.00 1/kg and 4.20 +/- 0.78 1/kg in the control group.,Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653644/),[1] / [kg],4.20,126614,DB00333,Methadone
,6653644,t1/2 beta,Differences between the groups were also found in t1/2 beta - 24.5 +/- 2.6 h in the therapeutic failures and 34.0 +/- 7.0 h (p less than 0.001) in the comparison group.,Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653644/),h,24.5,126615,DB00333,Methadone
,6653644,t1/2 beta,Differences between the groups were also found in t1/2 beta - 24.5 +/- 2.6 h in the therapeutic failures and 34.0 +/- 7.0 h (p less than 0.001) in the comparison group.,Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653644/),h,34.0,126616,DB00333,Methadone
,6653644,body clearance,"However, the change in t1/2 beta was probably a consequence of the change in Vd beta, as the body clearance of M was similar in the two groups - 104 +/- 36 ml/min vs 111 +/- 36 ml/min.",Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653644/),[ml] / [min],104,126617,DB00333,Methadone
,6653644,body clearance,"However, the change in t1/2 beta was probably a consequence of the change in Vd beta, as the body clearance of M was similar in the two groups - 104 +/- 36 ml/min vs 111 +/- 36 ml/min.",Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653644/),[ml] / [min],111,126618,DB00333,Methadone
,15089813,t(max),"Miosis t(max) (0.3 +/- 0.3 vs 0.3 +/- 0.2 h (-0.17, 0.22)), peak (5.3 +/- 0.8 vs 5.1 +/- 1.0 mm (0.39, 0.84)) and AUC vs time (25.0 +/- 5.7 vs 26.8 +/- 7.1 mm h (-6.1, 2.5)) were unchanged (placebo vs quinidine (95% confidence interval on the difference)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),h,0.3,129487,DB00333,Methadone
,15089813,t(max),"Miosis t(max) (0.3 +/- 0.3 vs 0.3 +/- 0.2 h (-0.17, 0.22)), peak (5.3 +/- 0.8 vs 5.1 +/- 1.0 mm (0.39, 0.84)) and AUC vs time (25.0 +/- 5.7 vs 26.8 +/- 7.1 mm h (-6.1, 2.5)) were unchanged (placebo vs quinidine (95% confidence interval on the difference)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),h,0.3,129488,DB00333,Methadone
,15089813,peak,"Miosis t(max) (0.3 +/- 0.3 vs 0.3 +/- 0.2 h (-0.17, 0.22)), peak (5.3 +/- 0.8 vs 5.1 +/- 1.0 mm (0.39, 0.84)) and AUC vs time (25.0 +/- 5.7 vs 26.8 +/- 7.1 mm h (-6.1, 2.5)) were unchanged (placebo vs quinidine (95% confidence interval on the difference)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),mm,5.3,129489,DB00333,Methadone
,15089813,peak,"Miosis t(max) (0.3 +/- 0.3 vs 0.3 +/- 0.2 h (-0.17, 0.22)), peak (5.3 +/- 0.8 vs 5.1 +/- 1.0 mm (0.39, 0.84)) and AUC vs time (25.0 +/- 5.7 vs 26.8 +/- 7.1 mm h (-6.1, 2.5)) were unchanged (placebo vs quinidine (95% confidence interval on the difference)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),mm,5.1,129490,DB00333,Methadone
,15089813,AUC vs time,"Miosis t(max) (0.3 +/- 0.3 vs 0.3 +/- 0.2 h (-0.17, 0.22)), peak (5.3 +/- 0.8 vs 5.1 +/- 1.0 mm (0.39, 0.84)) and AUC vs time (25.0 +/- 5.7 vs 26.8 +/- 7.1 mm h (-6.1, 2.5)) were unchanged (placebo vs quinidine (95% confidence interval on the difference)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),h·mm,25.0,129491,DB00333,Methadone
,15089813,AUC vs time,"Miosis t(max) (0.3 +/- 0.3 vs 0.3 +/- 0.2 h (-0.17, 0.22)), peak (5.3 +/- 0.8 vs 5.1 +/- 1.0 mm (0.39, 0.84)) and AUC vs time (25.0 +/- 5.7 vs 26.8 +/- 7.1 mm h (-6.1, 2.5)) were unchanged (placebo vs quinidine (95% confidence interval on the difference)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),h·mm,26.8,129492,DB00333,Methadone
,15089813,t(max),"Quinidine increased (P < 0.05) plasma methadone concentrations during the absorptive phase, decreased t(max) (2.4 +/- 0.7 vs 1.6 +/- 0.9 h (0.33, 1.2)), and increased peak miosis (3.2 +/- 1.5 vs 4.3 +/- 1.6 mm (-1.96, -0.19)) after oral methadone.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),h,2.4,129493,DB00333,Methadone
,15089813,t(max),"Quinidine increased (P < 0.05) plasma methadone concentrations during the absorptive phase, decreased t(max) (2.4 +/- 0.7 vs 1.6 +/- 0.9 h (0.33, 1.2)), and increased peak miosis (3.2 +/- 1.5 vs 4.3 +/- 1.6 mm (-1.96, -0.19)) after oral methadone.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),h,1.6,129494,DB00333,Methadone
,15089813,peak miosis,"Quinidine increased (P < 0.05) plasma methadone concentrations during the absorptive phase, decreased t(max) (2.4 +/- 0.7 vs 1.6 +/- 0.9 h (0.33, 1.2)), and increased peak miosis (3.2 +/- 1.5 vs 4.3 +/- 1.6 mm (-1.96, -0.19)) after oral methadone.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),mm,3.2,129495,DB00333,Methadone
,15089813,peak miosis,"Quinidine increased (P < 0.05) plasma methadone concentrations during the absorptive phase, decreased t(max) (2.4 +/- 0.7 vs 1.6 +/- 0.9 h (0.33, 1.2)), and increased peak miosis (3.2 +/- 1.5 vs 4.3 +/- 1.6 mm (-1.96, -0.19)) after oral methadone.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),mm,4.3,129496,DB00333,Methadone
,15089813,C(max),"The C(max) (55.6 +/- 10.3 vs 59.4 +/- 14.1 ng ml(-1) (-8.5, 0.65)) and AUC of methadone (298 +/- 46 vs 316 +/- 74 ng ml(-1) h (-54, 18)) were unchanged, as were the EDDP : methadone AUC ratios.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),[ng] / [ml],55.6,129497,DB00333,Methadone
,15089813,C(max),"The C(max) (55.6 +/- 10.3 vs 59.4 +/- 14.1 ng ml(-1) (-8.5, 0.65)) and AUC of methadone (298 +/- 46 vs 316 +/- 74 ng ml(-1) h (-54, 18)) were unchanged, as were the EDDP : methadone AUC ratios.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),[ng] / [ml],59.4,129498,DB00333,Methadone
,15089813,AUC,"The C(max) (55.6 +/- 10.3 vs 59.4 +/- 14.1 ng ml(-1) (-8.5, 0.65)) and AUC of methadone (298 +/- 46 vs 316 +/- 74 ng ml(-1) h (-54, 18)) were unchanged, as were the EDDP : methadone AUC ratios.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),[-54·h·ng] / [ml],298,129499,DB00333,Methadone
,15089813,AUC,"The C(max) (55.6 +/- 10.3 vs 59.4 +/- 14.1 ng ml(-1) (-8.5, 0.65)) and AUC of methadone (298 +/- 46 vs 316 +/- 74 ng ml(-1) h (-54, 18)) were unchanged, as were the EDDP : methadone AUC ratios.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),[-54·h·ng] / [ml],316,129500,DB00333,Methadone
,15089813,rate constant,"Quinidine had no effect on the rate constant for transfer of methadone between plasma and effect compartment (k(e0)) (2.6 +/- 2.6 vs 2.5 +/- 1.4 h(-1) (-3.5, 4.2)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),1/[h],2.6,129501,DB00333,Methadone
,15089813,rate constant,"Quinidine had no effect on the rate constant for transfer of methadone between plasma and effect compartment (k(e0)) (2.6 +/- 2.6 vs 2.5 +/- 1.4 h(-1) (-3.5, 4.2)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),1/[h],2.5,129502,DB00333,Methadone
,33423953,terminal half-life,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),min,44.3,130142,DB00333,Methadone
,33423953,volume of distribution,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),[l] / [kg],0.43,130143,DB00333,Methadone
,33423953,plasma clearance,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),[ml] / [kg·min],7.77,130144,DB00333,Methadone
,25963997,Cmin,"The serum Cmin methadone level was 1124 nmol/L (range, 547-1581 nmol/L).",Effects of Hemodialysis on Methadone Pharmacokinetics and QTc. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963997/),[nM] / [l],1124,130946,DB00333,Methadone
,25963997,dialysate clearance,"Methadone dialysate clearance was 17.1 mL/min (range, 13.7-20.6 mL/min).",Effects of Hemodialysis on Methadone Pharmacokinetics and QTc. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963997/),[ml] / [min],17.1,130947,DB00333,Methadone
,25963997,Total loss,"Total loss in dialysate was 2.30% (range, 1,25-3,70%) of daily methadone intake.",Effects of Hemodialysis on Methadone Pharmacokinetics and QTc. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963997/),%,2.30,130948,DB00333,Methadone
,25963997,QTc,"QTc increased from 391 msec (range, 369-406 msec) to 445 msec (range, 407-479 msec), independently of serum methadone level, which may be explained by normalization of serum electrolytes.",Effects of Hemodialysis on Methadone Pharmacokinetics and QTc. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963997/),ms,391,130949,DB00333,Methadone
,25963997,QTc,"QTc increased from 391 msec (range, 369-406 msec) to 445 msec (range, 407-479 msec), independently of serum methadone level, which may be explained by normalization of serum electrolytes.",Effects of Hemodialysis on Methadone Pharmacokinetics and QTc. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963997/),ms,445,130950,DB00333,Methadone
,9584342,elimination half-life,"Pharmacokinetic data sets for dextromoramide in each subject were conducted and analysed further, indicating short elimination half-life values (71 min, range 31-152 min).",Determination and pharmacokinetics of dextromoramide in methadone maintenance therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584342/),min,71,135834,DB00333,Methadone
,2039637,plasma half-life,This is consistent with sustained therapeutic plasma levels due to methadone's long plasma half-life (54 +/- 20 hours).,Postoperative pain control with methadone following lower abdominal surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039637/),h,54,141586,DB00333,Methadone
,19238656,hepatic,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),,0,141867,DB00333,Methadone
,19238656,intestinal extraction,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),,0,141868,DB00333,Methadone
,19238656,bioavailability,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),%,37,141869,DB00333,Methadone
,19238656,bioavailability,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),%,95,141870,DB00333,Methadone
,20301952,concentration,The mean concentration of methadone in plasma of patients receiving 40 mg of drug per day was 194 ng/ml but in second group (receiving 90 mg of methadone/day) 263 ng/ml.,Developing of LC/MS method with microwave assisted extraction for determination of methadone and it major metabolite (EDDP) in the blood of patients of methadone maintenance treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20301952/),[ng] / [ml],194,142554,DB00333,Methadone
,18282261,elimination half-life,"The elimination half-life, volume of distribution, and plasma clearance were 1.53 +/- 0.18 hours, 7.79 +/- 1.87 L kg(-1), and 56.04 +/- 9.36 mL minute(-1) kg(-1), respectively.",The disposition and behavioral effects of methadone in Greyhounds. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282261/),h,1.53,143619,DB00333,Methadone
,18282261,volume of distribution,"The elimination half-life, volume of distribution, and plasma clearance were 1.53 +/- 0.18 hours, 7.79 +/- 1.87 L kg(-1), and 56.04 +/- 9.36 mL minute(-1) kg(-1), respectively.",The disposition and behavioral effects of methadone in Greyhounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282261/),[l] / [kg],7.79,143620,DB00333,Methadone
,18282261,plasma clearance,"The elimination half-life, volume of distribution, and plasma clearance were 1.53 +/- 0.18 hours, 7.79 +/- 1.87 L kg(-1), and 56.04 +/- 9.36 mL minute(-1) kg(-1), respectively.",The disposition and behavioral effects of methadone in Greyhounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282261/),[ml] / [kg·minute],56.04,143621,DB00333,Methadone
,29607939,clearance (CL/F),"The estimated clearance (CL/F) and distribution volume (Vd/F) of methadone were 2.84 L/h and 502.8 L, respectively, and took about two weeks to reach steady state.",A Novel Method for Determination of Methadone in the Serum by High-Performance Liquid Chromatography with Electrochemical Detection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29607939/),[l] / [h],2.84,144996,DB00333,Methadone
,29607939,distribution volume (Vd/F),"The estimated clearance (CL/F) and distribution volume (Vd/F) of methadone were 2.84 L/h and 502.8 L, respectively, and took about two weeks to reach steady state.",A Novel Method for Determination of Methadone in the Serum by High-Performance Liquid Chromatography with Electrochemical Detection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29607939/),l,502.8,144997,DB00333,Methadone
,27286724,QTc,"A linear model described the methadone concentration-QTc relationship, with a mean QTc increase of 9.9 ms and 19.2 ms per 1000 ng/ml of (R)- and (S)-methadone, respectively.",Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27286724/),ms,9,146559,DB00333,Methadone
,27286724,QTc,"A linear model described the methadone concentration-QTc relationship, with a mean QTc increase of 9.9 ms and 19.2 ms per 1000 ng/ml of (R)- and (S)-methadone, respectively.",Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27286724/),m,19,146560,DB00333,Methadone
,32513525,maximum concentration,"After IN administration, tramadol was rapidly absorbed into the systemic circulation, reaching its maximum concentration (range 74.74-200.29 ng mL-1) within 30-60 minutes, it then decreased rapidly and was detectable in plasma for up to 2 hours after treatment in all dogs.",Pharmacokinetics and analgesic efficacy of intranasal administration of tramadol in dogs after ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32513525/),[ng] / [ml],74.74-200.29,146664,DB00333,Methadone
,22280392,half-life,"Oral pharmacokinetics in horses included a short half-life (approx 1 hour), high total body clearance corrected for bioavailability (5 to 8 mL/min/kg), and small apparent volume of distribution corrected for bioavailability (0.6 to 0.9 L/kg).","Bioavailability and pharmacokinetics of oral and injectable formulations of methadone after intravenous, oral, and intragastric administration in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280392/),h,1,149743,DB00333,Methadone
,22280392,total body clearance corrected for bioavailability,"Oral pharmacokinetics in horses included a short half-life (approx 1 hour), high total body clearance corrected for bioavailability (5 to 8 mL/min/kg), and small apparent volume of distribution corrected for bioavailability (0.6 to 0.9 L/kg).","Bioavailability and pharmacokinetics of oral and injectable formulations of methadone after intravenous, oral, and intragastric administration in horses. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280392/),[ml] / [kg·min],5 to 8,149744,DB00333,Methadone
,22280392,apparent volume of distribution corrected for bioavailability,"Oral pharmacokinetics in horses included a short half-life (approx 1 hour), high total body clearance corrected for bioavailability (5 to 8 mL/min/kg), and small apparent volume of distribution corrected for bioavailability (0.6 to 0.9 L/kg).","Bioavailability and pharmacokinetics of oral and injectable formulations of methadone after intravenous, oral, and intragastric administration in horses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280392/),[l] / [kg],0.6 to 0.9,149745,DB00333,Methadone
,550136,apparent excretory half-life,The apparent excretory half-life of methadone in the neonate was 32.5 hr.,Methadone disposition during the perinatal period in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/550136/),h,32.5,150698,DB00333,Methadone
,3802690,bioavailability,Controlled release tablets had 86% the bioavailability of the solution.,Steady-state pharmacokinetics of controlled release oral morphine sulphate in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802690/),%,86,151204,DB00333,Methadone
,17099560,bioavailability,Its mean bioavailability is around 75%.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,75,153478,DB00333,Methadone
,17099560,volume of distribution,Its volume of distribution is of around 4 L/kg.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[l] / [kg],4,153479,DB00333,Methadone
,17099560,half-life elimination,The value of half-life elimination is of around 22 hours.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),h,22,153480,DB00333,Methadone
,17099560,bioavibility,"Thus, bioavibility ranges from 36 to 100%.",[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,36 to 100,153481,DB00333,Methadone
,17099560,plasmatic target,The methadone plasmatic target value of 400 microg/ml can be recommended for therapeutic drug monitoring.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[μg] / [ml],400,153482,DB00333,Methadone
,1599890,concentrations,Methadone concentrations increased significantly from 20 +/- 18 ng/ml (median +/- quartile) on postoperative Day 1 to 70 +/- 47 ng/ml on Day 3.,Continuous epidural methadone for the management of postoperative pain after lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1599890/),[ng] / [ml],20,154221,DB00333,Methadone
,1599890,concentrations,Methadone concentrations increased significantly from 20 +/- 18 ng/ml (median +/- quartile) on postoperative Day 1 to 70 +/- 47 ng/ml on Day 3.,Continuous epidural methadone for the management of postoperative pain after lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1599890/),[ng] / [ml],70,154222,DB00333,Methadone
,1599890,Pain relief scores,Pain relief scores steadily increased from 50 +/- 5 at 2 hours postoperatively to 83 +/- 5 by Day 3.,Continuous epidural methadone for the management of postoperative pain after lower abdominal surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1599890/),,50,154223,DB00333,Methadone
,1599890,Pain relief scores,Pain relief scores steadily increased from 50 +/- 5 at 2 hours postoperatively to 83 +/- 5 by Day 3.,Continuous epidural methadone for the management of postoperative pain after lower abdominal surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1599890/),,83,154224,DB00333,Methadone
,9431829,milk/plasma ratio,The mean (95% CI) milk/plasma ratio was 0.44 (0.24-0.64).,Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431829/),,0.44,156502,DB00333,Methadone
,9431829,bioavailability,"Exposure of the infants, calculated assuming an average milk intake of 0.15 l kg-1 day-1 and a bioavailability of 100% was 17.4 (10.8-24) microg kg-1 day-1.",Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431829/),[μg] / [d·kg],100,156503,DB00333,Methadone
,9431829,bioavailability,"Exposure of the infants, calculated assuming an average milk intake of 0.15 l kg-1 day-1 and a bioavailability of 100% was 17.4 (10.8-24) microg kg-1 day-1.",Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431829/),[μg] / [d·kg],17.4,156504,DB00333,Methadone
,15151520,clearance,"The population geometric mean (coefficient of variation) of maximum a posteriori probability Bayesian estimated values for clearance, terminal half-life and volume of distribution at steady-state of the active (R)-enantiomer were 8.7 (42%) l h(-1), 51 (45%) h and 597 (45%) l, respectively.","Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151520/),,8.7,157165,DB00333,Methadone
,15151520,terminal half-life,"The population geometric mean (coefficient of variation) of maximum a posteriori probability Bayesian estimated values for clearance, terminal half-life and volume of distribution at steady-state of the active (R)-enantiomer were 8.7 (42%) l h(-1), 51 (45%) h and 597 (45%) l, respectively.","Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151520/),,51,157166,DB00333,Methadone
,15151520,volume of distribution at steady-state,"The population geometric mean (coefficient of variation) of maximum a posteriori probability Bayesian estimated values for clearance, terminal half-life and volume of distribution at steady-state of the active (R)-enantiomer were 8.7 (42%) l h(-1), 51 (45%) h and 597 (45%) l, respectively.","Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151520/),,597,157167,DB00333,Methadone
,16885725,m/,The following ions were monitored: m/z 310.15 for unlabeled methadone; m/z 316.15 for methadone-d(6); and m/z 313.15 for the methadone-d(3) (internal standard).,Stereoselective quantification of methadone and a d(6)-labeled isotopomer using high performance liquid chromatography-atmospheric pressure chemical ionization mass-spectrometry: application to a pharmacokinetic study in a methadone maintained subject. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16885725/),,310.15,157296,DB00333,Methadone
,16885725,m/z,The following ions were monitored: m/z 310.15 for unlabeled methadone; m/z 316.15 for methadone-d(6); and m/z 313.15 for the methadone-d(3) (internal standard).,Stereoselective quantification of methadone and a d(6)-labeled isotopomer using high performance liquid chromatography-atmospheric pressure chemical ionization mass-spectrometry: application to a pharmacokinetic study in a methadone maintained subject. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16885725/),,316.15,157297,DB00333,Methadone
,16885725,m/z,The following ions were monitored: m/z 310.15 for unlabeled methadone; m/z 316.15 for methadone-d(6); and m/z 313.15 for the methadone-d(3) (internal standard).,Stereoselective quantification of methadone and a d(6)-labeled isotopomer using high performance liquid chromatography-atmospheric pressure chemical ionization mass-spectrometry: application to a pharmacokinetic study in a methadone maintained subject. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16885725/),,313.15,157298,DB00333,Methadone
,16885725,Extraction recovery,"Extraction recovery was approximately 80% for all analytes, without evidence of differences between the unlabeled and stable-labeled compounds or concentration dependency.",Stereoselective quantification of methadone and a d(6)-labeled isotopomer using high performance liquid chromatography-atmospheric pressure chemical ionization mass-spectrometry: application to a pharmacokinetic study in a methadone maintained subject. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16885725/),%,80,157299,DB00333,Methadone
,12701853,time required to achieve good pain control,The median time required to achieve good pain control was three days (range 1-11 days).,An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12701853/),d,three,166520,DB00333,Methadone
>,32486995,bioavailability,For drugs with a high bioavailability (> 70 %) only the impaired hepatic clearance has to be considered.,[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167613,DB00333,Methadone
>,32486995,bioavailability,"Buprenorphine, fentanyl, hydromorphone, morphine, naloxone und tapentadol are drugs with a high first-pass effect, while the bioavailability of methadone, oxycodone and tramadol is > 70 %.",[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167614,DB00333,Methadone
,238782,apparent half-life,The mean apparent half-life was 7 hr.,Disposition of acetylmethadol in relation to pharmacologic action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/238782/),h,7,168413,DB00333,Methadone
,238782,apparent half-life,The mean apparent half-life of noracetylmethadol was 48 hr.,Disposition of acetylmethadol in relation to pharmacologic action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/238782/),h,48,168414,DB00333,Methadone
,27044652,anae,"Mean anaesthesia time and time to extubation in the TCI-2 group were 73.90 (±20.29) and 8.04 (±5.46) minutes, respectively.",Evaluation and optimisation of propofol pharmacokinetic parameters in cats for target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044652/),min,73.90,170769,DB00333,Methadone
,27044652,time,"Mean anaesthesia time and time to extubation in the TCI-2 group were 73.90 (±20.29) and 8.04 (±5.46) minutes, respectively.",Evaluation and optimisation of propofol pharmacokinetic parameters in cats for target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044652/),min,73.90,170770,DB00333,Methadone
,27044652,time to extubation,"Mean anaesthesia time and time to extubation in the TCI-2 group were 73.90 (±20.29) and 8.04 (±5.46) minutes, respectively.",Evaluation and optimisation of propofol pharmacokinetic parameters in cats for target-controlled infusion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044652/),min,8.04,170771,DB00333,Methadone
,7988100,terminal elimination half-life,"Following administration of single doses, fluvoxamine shows a biphasic elimination with a mean terminal elimination half-life of about 15 to 20 hours.",Clinical pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988100/),h,15 to 20,171285,DB00333,Methadone
,14973306,EC(50),"SQV trough concentrations exceeded the anticipated EC(50) (50 ng/mL) in 10/12 subjects, persisting for at least 6 hours after the final dose in 4/6 subjects.",The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973306/),[ng] / [ml],50,171624,DB00333,Methadone
,28827023,total plasma concentrations,"Median (interquartile) total plasma concentrations for l- and d-methadone were 50.78 ng/mL (30.6-113.0 ng/mL) and 62.0 ng/mL (28.7-116.0 ng/mL), respectively.",Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28827023/),[ng] / [ml],50.78,174441,DB00333,Methadone
,28827023,total plasma concentrations,"Median (interquartile) total plasma concentrations for l- and d-methadone were 50.78 ng/mL (30.6-113.0 ng/mL) and 62.0 ng/mL (28.7-116.0 ng/mL), respectively.",Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28827023/),[ng] / [ml],62.0,174442,DB00333,Methadone
,28827023,saliva concentrations,Median (interquartile range) saliva concentrations for l- and d-methadone were 81.5 ng/mL (28.0-203.2 ng/mL) and 44.2 (16.2-149.7 ng/mL).,Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28827023/),[ng] / [ml],81.5,174443,DB00333,Methadone
,28827023,saliva concentrations,Median (interquartile range) saliva concentrations for l- and d-methadone were 81.5 ng/mL (28.0-203.2 ng/mL) and 44.2 (16.2-149.7 ng/mL).,Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28827023/),[ng] / [ml],44.2,174444,DB00333,Methadone
,34273481,fetal/maternal plasma concentration ratio,The median fetal/maternal plasma concentration ratio was 13 - 27 % throughout the exposure period at baseline.,MATERNAL AND FETAL BUPRENORPHINE PHARMACOKINETICS IN PREGNANT SHEEP DURING TRANSDERMAL PATCH DOSING: Buprenorphine pharmacokinetics in pregnant sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34273481/),%,13 - 27,177680,DB00333,Methadone
,15255797,absolute rectal bioavailability,"The mean absolute rectal bioavailability of methadone was 0.76 (0.7, 0.81), compared to 0.86 (0.75, 0.97) for oral administration (mean (95% CI)).",Bioavailabilities of rectal and oral methadone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15255797/),,0.76,181180,DB00333,Methadone
,15255797,absolute rectal bioavailability,"The mean absolute rectal bioavailability of methadone was 0.76 (0.7, 0.81), compared to 0.86 (0.75, 0.97) for oral administration (mean (95% CI)).",Bioavailabilities of rectal and oral methadone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15255797/),,0.86,181181,DB00333,Methadone
,15255797,Tmax,"Rectal absorption of methadone was more rapid than after oral dosing with Tmax values of 1.4 (0.9, 1.8) vs. 2.8 (1.6, 4.0) h.",Bioavailabilities of rectal and oral methadone in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15255797/),h,1.4,181182,DB00333,Methadone
,15255797,Tmax,"Rectal absorption of methadone was more rapid than after oral dosing with Tmax values of 1.4 (0.9, 1.8) vs. 2.8 (1.6, 4.0) h.",Bioavailabilities of rectal and oral methadone in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15255797/),h,2.8,181183,DB00333,Methadone
,15255797,duration of action,Single doses of methadone had a duration of action of at least 10 h and were well tolerated.,Bioavailabilities of rectal and oral methadone in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15255797/),h,10,181184,DB00333,Methadone
,7844961,Overall elimination half-life (t1/2),Overall elimination half-life (t1/2) was 1.38 h.,Pharmacokinetic properties of methadone hydrochloride after single intramuscular administration in adult dairy goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7844961/),h,1.38,182278,DB00333,Methadone
,7844961,plasma concentration,"Peak plasma concentrations were reached 0.25 h after dosing, and the actual plasma concentration averaged 37.8 ng/ml (SD = 12.76) at that time.",Pharmacokinetic properties of methadone hydrochloride after single intramuscular administration in adult dairy goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7844961/),[ng] / [ml],37.8,182279,DB00333,Methadone
,26364984,oral clearance,"The population mean estimates (coefficient of variation percentage) for oral clearance and volume of distribution were 8.94 (103%) L/h/70 kg and 177 (133%) L/70 kg, respectively.",Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364984/),,8.94,182749,DB00333,Methadone
,26364984,volume of distribution,"The population mean estimates (coefficient of variation percentage) for oral clearance and volume of distribution were 8.94 (103%) L/h/70 kg and 177 (133%) L/70 kg, respectively.",Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364984/),,177,182750,DB00333,Methadone
,7286059,beta-phase plasma half-lives,"The beta-phase plasma half-lives varied five-fold, with a range from 8.5 to 47 h.",Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286059/),h,8.5 to 47,185067,DB00333,Methadone
,7286059,apparent volumes of distribution,The apparent volumes of distribution varied from 2.1 to 5.6 l/kg.,Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286059/),[l] / [kg],2.1 to 5.6,185068,DB00333,Methadone
exceeding,7286059,bioavailability,"Five patients had a bioavailability exceeding 90%, and three had lower bioavailabilities of between 41 and 76%.",Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286059/),%,90,185069,DB00333,Methadone
,7286059,bioavailabilities,"Five patients had a bioavailability exceeding 90%, and three had lower bioavailabilities of between 41 and 76%.",Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286059/),%,41 and 76,185070,DB00333,Methadone
higher,7286059,bioavailability,"The data show that for a majority of these subjects the bioavailability was higher than 45%, the previously reported value.",Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286059/),%,45,185071,DB00333,Methadone
,29521669,MMRs,Previous research found average MMRs in nonpregnant populations of between 11.3 and 12.7.,The Use of Serum Methadone/Metabolite Ratios to Monitor Changing Perinatal Pharmacokinetics. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29521669/),,11.3 and 12.7,185333,DB00333,Methadone
,29521669,MMR,The average MMR during pregnancy was 6.1.,The Use of Serum Methadone/Metabolite Ratios to Monitor Changing Perinatal Pharmacokinetics. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29521669/),,6.1,185334,DB00333,Methadone
,9390725,Peak resolutions,Peak resolutions are about 2.0 for Mtd enantiomers.,Enantioselective high-performance liquid chromatography determination of methadone enantiomers and its major metabolite in human biological fluids using a new derivatized cyclodextrin-bonded phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9390725/),,2.0,186502,DB00333,Methadone
,1349495,peak plasma dipipanone concentration,"The mean peak plasma dipipanone concentration was 29 ng ml-1, the time to peak plasma concentration was 1-2 h, the mean elimination half-life was 3.5 h and the mean AUC was 156 ng ml-1 min.",Pharmacokinetics of dipipanone after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1349495/),[ng] / [ml],29,187977,DB00333,Methadone
,1349495,time to peak plasma concentration,"The mean peak plasma dipipanone concentration was 29 ng ml-1, the time to peak plasma concentration was 1-2 h, the mean elimination half-life was 3.5 h and the mean AUC was 156 ng ml-1 min.",Pharmacokinetics of dipipanone after a single oral dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1349495/),h,1-2,187978,DB00333,Methadone
,1349495,elimination half-life,"The mean peak plasma dipipanone concentration was 29 ng ml-1, the time to peak plasma concentration was 1-2 h, the mean elimination half-life was 3.5 h and the mean AUC was 156 ng ml-1 min.",Pharmacokinetics of dipipanone after a single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1349495/),h,3.5,187979,DB00333,Methadone
,1349495,AUC,"The mean peak plasma dipipanone concentration was 29 ng ml-1, the time to peak plasma concentration was 1-2 h, the mean elimination half-life was 3.5 h and the mean AUC was 156 ng ml-1 min.",Pharmacokinetics of dipipanone after a single oral dose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1349495/),[min·ng] / [ml],156,187980,DB00333,Methadone
,18479171,absolute bioavailability,The absolute bioavailability of abacavir is approximately 83%.,A review of the pharmacokinetics of abacavir. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),%,83,188444,DB00333,Methadone
,18479171,peak concentration,"To date, one study has assessed the steady-state pharmacokinetics of abacavir following a 600-mg once-daily regimen, and reported a geometric mean steady-state abacavir peak concentration of 3.85 microg/mL.",A review of the pharmacokinetics of abacavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),[μg] / [ml],3.85,188445,DB00333,Methadone
,18479171,peak concentration,"Although this concentration is higher than the steady-state abacavir peak concentration reported following a 300-mg twice-daily regimen (0.88-3.19 microg/mL, depending on the study), the geometric mean steady-state abacavir exposure over 24 hours was similar following these regimens.",A review of the pharmacokinetics of abacavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),[μg] / [ml],0.88-3.19,188446,DB00333,Methadone
,18479171,apparent volume of distribution,"The apparent volume of distribution of abacavir after intravenous administration is approximately 0.86 +/- 0.15 L/kg, suggesting that abacavir is distributed to extravascular spaces.",A review of the pharmacokinetics of abacavir. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),[l] / [kg],0.86,188447,DB00333,Methadone
,18479171,Binding,Binding to plasma proteins is about 50% and is independent of the plasma abacavir concentration.,A review of the pharmacokinetics of abacavir. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),%,50,188448,DB00333,Methadone
,18479171,terminal elimination half-life,The terminal elimination half-life of abacavir is approximately 1.5 hours.,A review of the pharmacokinetics of abacavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),h,1.5,188449,DB00333,Methadone
>,18479171,elimination half-life,"When assessed by validated high-performance liquid chromatography electrospray ionization tandem mass spectrometry, CBV-TP has been shown to have a long elimination half-life (>20 hours), supporting once-daily dosing.",A review of the pharmacokinetics of abacavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),h,20,188450,DB00333,Methadone
,31806432,target plasma concentration (TPC),"Dogs were allocated to group fTCI [target plasma concentration (TPC) 1 ng mL-1] or group PNB (nerve stimulator-guided femoral-sciatic block using 0.2 and 0.1 mL kg-1 of levobupivacaine 0.5%, respectively).",Peripheral nerve block versus systemic analgesia in dogs undergoing tibial plateau levelling osteotomy: Analgesic efficacy and pharmacoeconomics comparison. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806432/),[ng] / [ml],1,190829,DB00333,Methadone
,7106170,oral bioavailability,The oral bioavailability of a methadone solution was found to be between 81 and 95%: elimination half-life in the beta-phase varied between 19 and 58 h; the volume of distribution was 4.1 +/- 0.65 l/kg; and total body clearance of M was 54-195 ml/min and its renal clearance 3.4-34 ml/min.,Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106170/),%,81 and 95,191046,DB00333,Methadone
,7106170,elimination half-life in the beta-phase,The oral bioavailability of a methadone solution was found to be between 81 and 95%: elimination half-life in the beta-phase varied between 19 and 58 h; the volume of distribution was 4.1 +/- 0.65 l/kg; and total body clearance of M was 54-195 ml/min and its renal clearance 3.4-34 ml/min.,Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106170/),h,19 and 58,191047,DB00333,Methadone
,7106170,volume of distribution,The oral bioavailability of a methadone solution was found to be between 81 and 95%: elimination half-life in the beta-phase varied between 19 and 58 h; the volume of distribution was 4.1 +/- 0.65 l/kg; and total body clearance of M was 54-195 ml/min and its renal clearance 3.4-34 ml/min.,Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106170/),[l] / [kg],4.1,191048,DB00333,Methadone
,7106170,total body clearance,The oral bioavailability of a methadone solution was found to be between 81 and 95%: elimination half-life in the beta-phase varied between 19 and 58 h; the volume of distribution was 4.1 +/- 0.65 l/kg; and total body clearance of M was 54-195 ml/min and its renal clearance 3.4-34 ml/min.,Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106170/),[ml] / [min],54-195,191049,DB00333,Methadone
,7106170,renal clearance,The oral bioavailability of a methadone solution was found to be between 81 and 95%: elimination half-life in the beta-phase varied between 19 and 58 h; the volume of distribution was 4.1 +/- 0.65 l/kg; and total body clearance of M was 54-195 ml/min and its renal clearance 3.4-34 ml/min.,Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106170/),[ml] / [min],3.4-34,191050,DB00333,Methadone
,15371986,oral bioavailability,"Methadone had high oral bioavailability (70%) and low intestinal (22%) and hepatic (9%) extraction, and there was a significant correlation ( r = 0.94, P <.001) between oral bioavailability and intestinal (but not hepatic) availability.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),%,70,192332,DB00333,Methadone
,15371986,oral bioavailability,"Methadone had high oral bioavailability (70%) and low intestinal (22%) and hepatic (9%) extraction, and there was a significant correlation ( r = 0.94, P <.001) between oral bioavailability and intestinal (but not hepatic) availability.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),%,22,192333,DB00333,Methadone
,15371986,oral bioavailability,"Methadone had high oral bioavailability (70%) and low intestinal (22%) and hepatic (9%) extraction, and there was a significant correlation ( r = 0.94, P <.001) between oral bioavailability and intestinal (but not hepatic) availability.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),%,9,192334,DB00333,Methadone
,15371986,IV clearance,Rifampin decreased bioavailability and oral and IV methadone plasma concentrations and increased IV clearance (4.42 +/- 1.00 mL.,"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,4.42,192335,DB00333,Methadone
,15371986,oral clearance,"kg -1. min -1, P <.05) and oral clearance (8.50 +/- 3.68 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,8.50,192336,DB00333,Methadone
,15371986,area under the curve (AUC) ratios,"kg -1. min -1, P <.05), EDDP/methadone area under the curve (AUC) ratios, EDDP formation clearances, and hepatic extraction (0.27 +/- 0.06 versus 0.09 +/- 0.04, P <.05).","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.27,192337,DB00333,Methadone
,15371986,formation clearances,"kg -1. min -1, P <.05), EDDP/methadone area under the curve (AUC) ratios, EDDP formation clearances, and hepatic extraction (0.27 +/- 0.06 versus 0.09 +/- 0.04, P <.05).","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.09,192338,DB00333,Methadone
,15371986,AUC ratio,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.17,192339,DB00333,Methadone
,15371986,AUC ratio,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.14,192340,DB00333,Methadone
,15371986,AUC ratio,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.27,192341,DB00333,Methadone
,15371986,IV,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,1.29,192342,DB00333,Methadone
,15371986,clearance,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,1.29,192343,DB00333,Methadone
,15371986,oral clearance,kg -1. min -1 ) or oral clearance (2.05 +/- 1.52 mL.,"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,2.05,192344,DB00333,Methadone
,10391674,N,"The mean N values were 5.4+/-0.9 for withdrawal severity, 5.1+/-1.1 for subjective opioid effects, 1.2+/-0.1 for pupil diameter, and 2.8+/-0.7 for pain threshold.",Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391674/),,5.1,198492,DB00333,Methadone
,10391674,N,"The mean N values were 5.4+/-0.9 for withdrawal severity, 5.1+/-1.1 for subjective opioid effects, 1.2+/-0.1 for pupil diameter, and 2.8+/-0.7 for pain threshold.",Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391674/),,1.2,198493,DB00333,Methadone
,10391674,pain threshold,"The mean N values were 5.4+/-0.9 for withdrawal severity, 5.1+/-1.1 for subjective opioid effects, 1.2+/-0.1 for pupil diameter, and 2.8+/-0.7 for pain threshold.",Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391674/),,1.2,198494,DB00333,Methadone
,10391674,pain threshold,"The mean N values were 5.4+/-0.9 for withdrawal severity, 5.1+/-1.1 for subjective opioid effects, 1.2+/-0.1 for pupil diameter, and 2.8+/-0.7 for pain threshold.",Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391674/),,2.8,198495,DB00333,Methadone
,10391674,maximal rate of decline,"There were no differences between those who reported significant withdrawal and those who did not with respect to mean area under the plasma concentration versus time curve and predose plasma concentration, but maximal rate of decline was greater in the former group (74.5 versus 42.1 ng/mL/h).",Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391674/),[ng] / [h·ml],74.5,198496,DB00333,Methadone
,10391674,maximal rate of decline,"There were no differences between those who reported significant withdrawal and those who did not with respect to mean area under the plasma concentration versus time curve and predose plasma concentration, but maximal rate of decline was greater in the former group (74.5 versus 42.1 ng/mL/h).",Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391674/),[ng] / [h·ml],42.1,198497,DB00333,Methadone
,16284915,apparent volume,"Lung kinetics displayed clear stereoselectivity, due to the smaller apparent volume of the deep lung compartment for (R)-methadone (45 l) compared to (S)-methadone (79 l).",The acute disposition of (R)- and (s)-methadone in brain and lung of sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284915/),l,45,199936,DB00333,Methadone
,16284915,apparent volume,"Lung kinetics displayed clear stereoselectivity, due to the smaller apparent volume of the deep lung compartment for (R)-methadone (45 l) compared to (S)-methadone (79 l).",The acute disposition of (R)- and (s)-methadone in brain and lung of sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284915/),l,79,199937,DB00333,Methadone
,16284915,half-life,The brain:blood equilibration of methadone was slow (half-life of 18 min) due to intermediate permeability and large apparent cerebral distribution volumes.,The acute disposition of (R)- and (s)-methadone in brain and lung of sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284915/),min,18,199938,DB00333,Methadone
,15907650,half-lives,Alfentanil and remifentanil are very fast equilibrating opioids with equilibration half-lives between plasma and effect site of about 1 minute.,Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,1,199979,DB00333,Methadone
,15907650,half-lives,"They are followed by fentanyl and sufentanil, each with equilibration half-lives of about 6 min.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,6,199980,DB00333,Methadone
,15907650,half-life,Methadone equilibrates with a half-life of about 8 min.,Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,8,199981,DB00333,Methadone
,15907650,half-life,"Morphine, in contrast, equilibrates with a half-life of 2-3 h.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),h,2-3,199982,DB00333,Methadone
,15907650,half-life,"The slowest opioid with respect to plasma-effect site transfer is M6G, with an equilibration half-life of about 7 h.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),h,7,199983,DB00333,Methadone
,8453965,Ka,"Analysis of the plasma concentration-time curves gave estimates of the variance of methadone clearance and apparent volume of distribution, and indicate that methadone is rapidly absorbed (mean Ka, 1.7 h-1) with a detectable increase in the plasma drug concentration 15 to 30 min after dosing.",Steady-state pharmacokinetics of methadone in opioid addicts. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453965/),1/[h],1.7,200092,DB00333,Methadone
,8453965,t1/2,The elimination of methadone from plasma was found to occur slowly (mean t1/2 26.8 h) beginning soon after the administration of the daily oral prescription.,Steady-state pharmacokinetics of methadone in opioid addicts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453965/),h,26.8,200093,DB00333,Methadone
,8453965,apparent volume of distribution,The apparent volume of distribution-assuming the oral bioavailability (f) of methadone to be 0.95--was large (mean 6.7 l.kg-1).,Steady-state pharmacokinetics of methadone in opioid addicts. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453965/),[l] / [kg],0.95,200094,DB00333,Methadone
,8453965,apparent volume of distribution,The apparent volume of distribution-assuming the oral bioavailability (f) of methadone to be 0.95--was large (mean 6.7 l.kg-1).,Steady-state pharmacokinetics of methadone in opioid addicts. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453965/),[l] / [kg],6.7,200095,DB00333,Methadone
,8453965,oral bioavailability (f),The apparent volume of distribution-assuming the oral bioavailability (f) of methadone to be 0.95--was large (mean 6.7 l.kg-1).,Steady-state pharmacokinetics of methadone in opioid addicts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453965/),[l] / [kg],0.95,200096,DB00333,Methadone
,8453965,oral bioavailability (f),The apparent volume of distribution-assuming the oral bioavailability (f) of methadone to be 0.95--was large (mean 6.7 l.kg-1).,Steady-state pharmacokinetics of methadone in opioid addicts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453965/),[l] / [kg],6.7,200097,DB00333,Methadone
,8453965,clearance,The slow clearance of this drug from the body (mean 3.1 ml.min-1.kg-1) confirms that daily dosing at steady-state is adequate to maintain effective plasma concentrations throughout the dosing interval.,Steady-state pharmacokinetics of methadone in opioid addicts. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453965/),[ml] / [kg·min],3.1,200098,DB00333,Methadone
,7737438,serum half-life,After a single injection with 20 mg/kg methadone a pharmacokinetic analysis revealed a serum half-life of approximately 2 hr.,The effect of methadone on the immune status of B6C3F1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7737438/),h,2,202382,DB00333,Methadone
,7946975,clearance,"Stereoselective differences were evident following administration of the racemate (P values for differences in AUC and CL were 0.01 and 0.046, respectively) and the clearance of the (S)-enantiomer was increased when administered as part of the racemate (316 +/- 81 vs 487 +/- 128 ml/min, P = 0.04).",Stereoselective pharmacokinetics of methadone in beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946975/),[ml] / [min],316,202476,DB00333,Methadone
,7946975,clearance,"Stereoselective differences were evident following administration of the racemate (P values for differences in AUC and CL were 0.01 and 0.046, respectively) and the clearance of the (S)-enantiomer was increased when administered as part of the racemate (316 +/- 81 vs 487 +/- 128 ml/min, P = 0.04).",Stereoselective pharmacokinetics of methadone in beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946975/),[ml] / [min],487,202477,DB00333,Methadone
,33461553,volume of distribution,For methadone a volume of distribution of 10.26 l kg- 1 and a terminal half-life of 2.4 h were detected and a clearance of 51.44 ml kg- 1 min- 1 was calculated.,Plasma levels of a methadone constant rate infusion and their corresponding effects on thermal and mechanical nociceptive thresholds in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33461553/),1·kg-·l,10.26,204880,DB00333,Methadone
,33461553,terminal half-life,For methadone a volume of distribution of 10.26 l kg- 1 and a terminal half-life of 2.4 h were detected and a clearance of 51.44 ml kg- 1 min- 1 was calculated.,Plasma levels of a methadone constant rate infusion and their corresponding effects on thermal and mechanical nociceptive thresholds in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33461553/),h,2.4,204881,DB00333,Methadone
,33461553,clearance,For methadone a volume of distribution of 10.26 l kg- 1 and a terminal half-life of 2.4 h were detected and a clearance of 51.44 ml kg- 1 min- 1 was calculated.,Plasma levels of a methadone constant rate infusion and their corresponding effects on thermal and mechanical nociceptive thresholds in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33461553/),1·1·kg-·min-·ml,51.44,204882,DB00333,Methadone
,1149368,primary half-life (t1/2),The acute primary half-life (t1/2) of 14.3 hr in combination with the acute secondary t1/2 of 54.8 hr were longer than the single exponential chronic t1/2 of 22.2 hr determined in the same subjects.,Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149368/),h,14.3,205576,DB00333,Methadone
,1149368,secondary,The acute primary half-life (t1/2) of 14.3 hr in combination with the acute secondary t1/2 of 54.8 hr were longer than the single exponential chronic t1/2 of 22.2 hr determined in the same subjects.,Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149368/),h,54.8,205577,DB00333,Methadone
,1149368,t1/2,The acute primary half-life (t1/2) of 14.3 hr in combination with the acute secondary t1/2 of 54.8 hr were longer than the single exponential chronic t1/2 of 22.2 hr determined in the same subjects.,Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149368/),h,54.8,205578,DB00333,Methadone
,1149368,chronic t1/2,The acute primary half-life (t1/2) of 14.3 hr in combination with the acute secondary t1/2 of 54.8 hr were longer than the single exponential chronic t1/2 of 22.2 hr determined in the same subjects.,Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149368/),h,22.2,205579,DB00333,Methadone
,27870477,t1/2,"Noribogaine had dose-linear increases for AUC and Cmax and was slowly eliminated (mean t1/2 range, 24-30 hours).","Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27870477/),h,24-30,207699,DB00333,Methadone
,22621465,maximum plasma drug concentration (C(max)),The pharmacokinetic parameters determined were: maximum plasma drug concentration (C(max)) of 38.1 ng/mL; time to reach C(max) (t(max)) of 2.80 hours; mean area under the plasma concentration-time curve (AUC) from time zero to 72 hours (AUC(72)) of 1043 ng · h/mL; mean AUC from time zero to infinity (AUC(∞)) of 1430 ng · h/mL; mean elimination rate constant (k(e)) of 0.0206 hours(-1); and mean elimination half-life (t(½)) of 36.7 hours.,Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621465/),[ng] / [ml],38.1,209778,DB00333,Methadone
,22621465,time to reach C(max) (t(max)),The pharmacokinetic parameters determined were: maximum plasma drug concentration (C(max)) of 38.1 ng/mL; time to reach C(max) (t(max)) of 2.80 hours; mean area under the plasma concentration-time curve (AUC) from time zero to 72 hours (AUC(72)) of 1043 ng · h/mL; mean AUC from time zero to infinity (AUC(∞)) of 1430 ng · h/mL; mean elimination rate constant (k(e)) of 0.0206 hours(-1); and mean elimination half-life (t(½)) of 36.7 hours.,Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621465/),h,2.80,209779,DB00333,Methadone
,22621465,area under the plasma concentration-time curve (AUC) from time zero to 72 hours (AUC(72)),The pharmacokinetic parameters determined were: maximum plasma drug concentration (C(max)) of 38.1 ng/mL; time to reach C(max) (t(max)) of 2.80 hours; mean area under the plasma concentration-time curve (AUC) from time zero to 72 hours (AUC(72)) of 1043 ng · h/mL; mean AUC from time zero to infinity (AUC(∞)) of 1430 ng · h/mL; mean elimination rate constant (k(e)) of 0.0206 hours(-1); and mean elimination half-life (t(½)) of 36.7 hours.,Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621465/),[h·ng] / [ml],1043,209780,DB00333,Methadone
,22621465,AUC from time zero to infinity (AUC(∞)),The pharmacokinetic parameters determined were: maximum plasma drug concentration (C(max)) of 38.1 ng/mL; time to reach C(max) (t(max)) of 2.80 hours; mean area under the plasma concentration-time curve (AUC) from time zero to 72 hours (AUC(72)) of 1043 ng · h/mL; mean AUC from time zero to infinity (AUC(∞)) of 1430 ng · h/mL; mean elimination rate constant (k(e)) of 0.0206 hours(-1); and mean elimination half-life (t(½)) of 36.7 hours.,Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621465/),[h·ng] / [ml],1430,209781,DB00333,Methadone
,22621465,elimination rate constant (k(e)),The pharmacokinetic parameters determined were: maximum plasma drug concentration (C(max)) of 38.1 ng/mL; time to reach C(max) (t(max)) of 2.80 hours; mean area under the plasma concentration-time curve (AUC) from time zero to 72 hours (AUC(72)) of 1043 ng · h/mL; mean AUC from time zero to infinity (AUC(∞)) of 1430 ng · h/mL; mean elimination rate constant (k(e)) of 0.0206 hours(-1); and mean elimination half-life (t(½)) of 36.7 hours.,Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621465/),1/[hours],0.0206,209782,DB00333,Methadone
,22621465,elimination half-life (t(½)),The pharmacokinetic parameters determined were: maximum plasma drug concentration (C(max)) of 38.1 ng/mL; time to reach C(max) (t(max)) of 2.80 hours; mean area under the plasma concentration-time curve (AUC) from time zero to 72 hours (AUC(72)) of 1043 ng · h/mL; mean AUC from time zero to infinity (AUC(∞)) of 1430 ng · h/mL; mean elimination rate constant (k(e)) of 0.0206 hours(-1); and mean elimination half-life (t(½)) of 36.7 hours.,Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621465/),h,36.7,209783,DB00333,Methadone
,25733012,AUC,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[h·ng] / [ml],6,209817,DB00333,Methadone
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[ng] / [ml],6,209818,DB00333,Methadone
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[h·ng] / [ml],541,209819,DB00333,Methadone
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[ng] / [ml],47.8,209820,DB00333,Methadone
,11177493,elimination half-life,"Auto-induction of methadone metabolism was demonstrated and it was observed that clearance of methadone was significantly lower (p < 0.05) in opiate addicts at the start of treatment (median elimination half-life, 128-hours) than in those who had reached steady-state (median elimination half-life, 48 hours).",Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11177493/),h,128,215454,DB00333,Methadone
,11177493,elimination half-life,"Auto-induction of methadone metabolism was demonstrated and it was observed that clearance of methadone was significantly lower (p < 0.05) in opiate addicts at the start of treatment (median elimination half-life, 128-hours) than in those who had reached steady-state (median elimination half-life, 48 hours).",Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11177493/),h,48,215455,DB00333,Methadone
,15735615,accumulation ratios,"The mean accumulation ratios (week 4/first dose) for C(max) and AUC from time 0 to 168 hours of peginterferon alfa-2a were 2.1 and 2.3, respectively.",Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735615/),,2.1,215717,DB00333,Methadone
,15735615,accumulation ratios,"The mean accumulation ratios (week 4/first dose) for C(max) and AUC from time 0 to 168 hours of peginterferon alfa-2a were 2.1 and 2.3, respectively.",Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735615/),,2.3,215718,DB00333,Methadone
,23478952,unbound C(min),The R-methadone median (absolute) unbound C(min) values in the absence (10.63 ng/ml) and presence (10.45 ng/ml) of telaprevir were similar.,Pharmacokinetic interaction between telaprevir and methadone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23478952/),[ng] / [ml],10.63,218800,DB00333,Methadone
,23478952,unbound C(min),The R-methadone median (absolute) unbound C(min) values in the absence (10.63 ng/ml) and presence (10.45 ng/ml) of telaprevir were similar.,Pharmacokinetic interaction between telaprevir and methadone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23478952/),[ng] / [ml],10.45,218801,DB00333,Methadone
,18477709,AUC,"The GM of the atazanavir AUC, C(max) and C(min) of men versus women were 32 643 versus 36 232 ng.h/mL [GM ratio (GMR) = 1.11, P = 0.435], 2802 versus 3211 ng/mL (GMR = 1.15, P = 0.305) and 398 versus 470 ng/mL (GMR = 1.18, P = 0.406), respectively.",The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477709/),[h·ng] / [ml],32 643,220541,DB00333,Methadone
,18477709,C(max),"The GM of the atazanavir AUC, C(max) and C(min) of men versus women were 32 643 versus 36 232 ng.h/mL [GM ratio (GMR) = 1.11, P = 0.435], 2802 versus 3211 ng/mL (GMR = 1.15, P = 0.305) and 398 versus 470 ng/mL (GMR = 1.18, P = 0.406), respectively.",The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477709/),[h·ng] / [ml],36 232,220542,DB00333,Methadone
,18477709,C(max),"The GM of the atazanavir AUC, C(max) and C(min) of men versus women were 32 643 versus 36 232 ng.h/mL [GM ratio (GMR) = 1.11, P = 0.435], 2802 versus 3211 ng/mL (GMR = 1.15, P = 0.305) and 398 versus 470 ng/mL (GMR = 1.18, P = 0.406), respectively.",The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477709/),[ng] / [ml],2802,220543,DB00333,Methadone
,18477709,C(max),"The GM of the atazanavir AUC, C(max) and C(min) of men versus women were 32 643 versus 36 232 ng.h/mL [GM ratio (GMR) = 1.11, P = 0.435], 2802 versus 3211 ng/mL (GMR = 1.15, P = 0.305) and 398 versus 470 ng/mL (GMR = 1.18, P = 0.406), respectively.",The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477709/),[ng] / [ml],3211,220544,DB00333,Methadone
,18477709,C(min),"The GM of the atazanavir AUC, C(max) and C(min) of men versus women were 32 643 versus 36 232 ng.h/mL [GM ratio (GMR) = 1.11, P = 0.435], 2802 versus 3211 ng/mL (GMR = 1.15, P = 0.305) and 398 versus 470 ng/mL (GMR = 1.18, P = 0.406), respectively.",The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477709/),[ng] / [ml],3211,220545,DB00333,Methadone
,18477709,C(min),"The GM of the atazanavir AUC, C(max) and C(min) of men versus women were 32 643 versus 36 232 ng.h/mL [GM ratio (GMR) = 1.11, P = 0.435], 2802 versus 3211 ng/mL (GMR = 1.15, P = 0.305) and 398 versus 470 ng/mL (GMR = 1.18, P = 0.406), respectively.",The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477709/),[ng] / [ml],398,220546,DB00333,Methadone
,18477709,C(min),"The GM of the atazanavir AUC, C(max) and C(min) of men versus women were 32 643 versus 36 232 ng.h/mL [GM ratio (GMR) = 1.11, P = 0.435], 2802 versus 3211 ng/mL (GMR = 1.15, P = 0.305) and 398 versus 470 ng/mL (GMR = 1.18, P = 0.406), respectively.",The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477709/),[ng] / [ml],470,220547,DB00333,Methadone
>,11219720,bioavailability,"Methadone release in vivo was estimated by deconvolution, F-PLGA giving a bioavailability >99% (methadone was totally released in 48h), while the estimated bioavailability of F-PLA was lower than expected.",In vivo-in vitro study of biodegradable methadone delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11219720/),%,99,220660,DB00333,Methadone
,11219720,bioavailability,"The bioavailability of the implant by deconvolution was around 60%, but absence of methadone in the implant indicated its complete release.",In vivo-in vitro study of biodegradable methadone delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11219720/),%,60,220661,DB00333,Methadone
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,95.9,220664,DB00333,Methadone
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,98,220665,DB00333,Methadone
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,94.8,220666,DB00333,Methadone
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,102.4,220667,DB00333,Methadone
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,1.8,220668,DB00333,Methadone
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,2.7,220669,DB00333,Methadone
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,3.9,220670,DB00333,Methadone
,26339186,limits of detection,"The limits of detection of MDN and EDDP were 4 and 5 ng/mL, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),[ng] / [ml],4,220671,DB00333,Methadone
,26339186,limits of detection,"The limits of detection of MDN and EDDP were 4 and 5 ng/mL, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),[ng] / [ml],5,220672,DB00333,Methadone
,30805946,Clearance,"Clearance increases with advancing gestational age and differs between R- and S-enantiomer, being slightly higher for the former (0.244 vs 0.167 L/h).",Methadone dosing strategies in preterm neonates can be simplified. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30805946/),[l] / [h],0.244,222281,DB00333,Methadone
,30805946,Clearance,"Clearance increases with advancing gestational age and differs between R- and S-enantiomer, being slightly higher for the former (0.244 vs 0.167 L/h).",Methadone dosing strategies in preterm neonates can be simplified. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30805946/),[l] / [h],0.167,222282,DB00333,Methadone
,28192759,flow rate,A gradient elution was employed with a mobile phase consisting of 5mM potassium phosphate containing 0.1% triethylamine (pH=6.5) (A) and acetonitrile (B) with a flow rate of 1mL/min.,Precise simultaneous quantification of methadone and cocaine in rat serum and brain tissue samples following their successive i.p. administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28192759/),[ml] / [min],1,222494,DB00333,Methadone
,682129,beta phase half-life,"After an intravenous infusion to male rabbits, the beta phase half-life was 106 +/- 21 min and the apparent volume of distribution was 12.6 liters/kg b.w.","Seminal excretion, vaginal absorption, distribution and whole blood kinetics of d-methadone in the rabbit. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/682129/),min,106,222774,DB00333,Methadone
,682129,apparent volume of distribution,"After an intravenous infusion to male rabbits, the beta phase half-life was 106 +/- 21 min and the apparent volume of distribution was 12.6 liters/kg b.w.","Seminal excretion, vaginal absorption, distribution and whole blood kinetics of d-methadone in the rabbit. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/682129/),[l] / [kg],12.6,222775,DB00333,Methadone
,682129,peak drug concentration,"After an i.m. injection, the peak drug concentration in arterial blood (1.02 microgram/ml) occurred 10 min after the injection, whereas the peak concentration in semen (2.58 microgram/ml) occurred 140 min later.","Seminal excretion, vaginal absorption, distribution and whole blood kinetics of d-methadone in the rabbit. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/682129/),[μg] / [ml],1.02,222776,DB00333,Methadone
,682129,peak concentration,"After an i.m. injection, the peak drug concentration in arterial blood (1.02 microgram/ml) occurred 10 min after the injection, whereas the peak concentration in semen (2.58 microgram/ml) occurred 140 min later.","Seminal excretion, vaginal absorption, distribution and whole blood kinetics of d-methadone in the rabbit. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/682129/),[μg] / [ml],2.58,222777,DB00333,Methadone
,682129,semen/blood drug concentration ratio,The semen/blood drug concentration ratio was 6.8 at 150 min after the injection.,"Seminal excretion, vaginal absorption, distribution and whole blood kinetics of d-methadone in the rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/682129/),,6.8,222778,DB00333,Methadone
,682129,peak drug level in blood,"After intravaginal implantation, d-methadone was rapidly absorbed into the systemic circulation of female rabbits; the peak drug level in blood (0.94 microgram/ml) occurred 60 min after drug administration.","Seminal excretion, vaginal absorption, distribution and whole blood kinetics of d-methadone in the rabbit. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/682129/),[μg] / [ml],0.94,222779,DB00333,Methadone
,7448349,Minimum detectable concentrations,"Minimum detectable concentrations are 10 ng ml-1 for acetylmethadol using a flame ionization detector, and 5 and 25 ng ml-1 for noracetylmethadol and dinoracetylmethadol respectively using electron capture detection.",Pharmacokinetics of acetylmethadols I: gas-liquid chromatographic determination of L-alpha-acetylmethadol and its major metabolites in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448349/),[ng] / [ml],10,228096,DB00333,Methadone
,7448349,Minimum detectable concentrations,"Minimum detectable concentrations are 10 ng ml-1 for acetylmethadol using a flame ionization detector, and 5 and 25 ng ml-1 for noracetylmethadol and dinoracetylmethadol respectively using electron capture detection.",Pharmacokinetics of acetylmethadols I: gas-liquid chromatographic determination of L-alpha-acetylmethadol and its major metabolites in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448349/),[ng] / [ml],5,228097,DB00333,Methadone
,7448349,Minimum detectable concentrations,"Minimum detectable concentrations are 10 ng ml-1 for acetylmethadol using a flame ionization detector, and 5 and 25 ng ml-1 for noracetylmethadol and dinoracetylmethadol respectively using electron capture detection.",Pharmacokinetics of acetylmethadols I: gas-liquid chromatographic determination of L-alpha-acetylmethadol and its major metabolites in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448349/),[ng] / [ml],25,228098,DB00333,Methadone
,16642964,terminal,"The estimated values for the exponents of the 1st, 2nd, and terminal compartments; volume of distribution at steady state; clearance; and area under the concentration-time curve were 12.8/h, 2.13/h, 0.239/h, 6.5 l/kg, 4.3 l/h/kg, and 559 microg/lxh, respectively.",Pharmacokinetics of buprenorphine after intravenous administration in the mouse. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16642964/),1/[h],12.8,228502,DB00333,Methadone
,16642964,area under the concentration-time curve,"The estimated values for the exponents of the 1st, 2nd, and terminal compartments; volume of distribution at steady state; clearance; and area under the concentration-time curve were 12.8/h, 2.13/h, 0.239/h, 6.5 l/kg, 4.3 l/h/kg, and 559 microg/lxh, respectively.",Pharmacokinetics of buprenorphine after intravenous administration in the mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16642964/),[μg] / [h·l],559,228503,DB00333,Methadone
>,16207309,oral bioavailability,"Methadone is an opioid, which has a high oral bioavailability (>70%) and a long elimination half-life (>20 h) in human beings.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),%,70,230489,DB00333,Methadone
>,16207309,elimination half-life,"Methadone is an opioid, which has a high oral bioavailability (>70%) and a long elimination half-life (>20 h) in human beings.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),h,20,230490,DB00333,Methadone
,16207309,elimination half-life,"The mean +/- SD for the elimination half-life, volume of distribution, and clearance were 1.75 +/- 0.25 h, 3.46 +/- 1.09 L/kg, and 25.14 +/- 9.79 mL/min.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),h,1.75,230491,DB00333,Methadone
,16207309,volume of distribution,"The mean +/- SD for the elimination half-life, volume of distribution, and clearance were 1.75 +/- 0.25 h, 3.46 +/- 1.09 L/kg, and 25.14 +/- 9.79 mL/min.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),[l] / [kg],3.46,230492,DB00333,Methadone
,16207309,clearance,"The mean +/- SD for the elimination half-life, volume of distribution, and clearance were 1.75 +/- 0.25 h, 3.46 +/- 1.09 L/kg, and 25.14 +/- 9.79 mL/min.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),[ml] / [min],25.14,230493,DB00333,Methadone
,16207309,bioavailability,"Following administration with ketoconazole, detectable concentrations of methadone were present in one dog with a 29% bioavailability.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),%,29,230494,DB00333,Methadone
,23884723,Cmin,"We describe the case of an intravenous drug user affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection with associated bacteraemia who, while on replacement therapy with methadone, required 11 mg/kg/day daptomycin to achieve trough (Cmin) and peak (Cmax) plasma levels similar to those observed with the standard dosage of 6 mg/kg in healthy volunteers (mean ± standard deviation: Cmin 12.35 ± 0.80 mg/L, Cmax 63.90 ± 8.71 mg/L).",Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884723/),[mg] / [l],12.35,231300,DB00333,Methadone
,23884723,Cmax,"We describe the case of an intravenous drug user affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection with associated bacteraemia who, while on replacement therapy with methadone, required 11 mg/kg/day daptomycin to achieve trough (Cmin) and peak (Cmax) plasma levels similar to those observed with the standard dosage of 6 mg/kg in healthy volunteers (mean ± standard deviation: Cmin 12.35 ± 0.80 mg/L, Cmax 63.90 ± 8.71 mg/L).",Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884723/),[mg] / [l],63.90,231301,DB00333,Methadone
,6163497,Plasma concentrations,Plasma concentrations of methadone varied sevenfold after four to five days (0.24 to 1.75 mumol/1; 7.4 to 54.2 microgram/100 ml).,Patient-controlled dose regimen of methadone for chronic cancer pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6163497/),μM,0.24 to 1.75,231568,DB00333,Methadone
,6163497,Plasma concentrations,Plasma concentrations of methadone varied sevenfold after four to five days (0.24 to 1.75 mumol/1; 7.4 to 54.2 microgram/100 ml).,Patient-controlled dose regimen of methadone for chronic cancer pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6163497/),[μg] / [100·ml],7.4 to 54.2,231569,DB00333,Methadone
,7171415,T1/2 alpha,Kinetic parameters derived from triexponential NONLIN analysis showed that T1/2 alpha and T1/2 beta were 2 and 30 min respectively; no reliable estimate for T1/2 gamma could be obtained.,Acute i.v. Methadone Kinetics in Man: relationship to chronic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7171415/),min,2,232554,DB00333,Methadone
,7171415,T1/2 beta,Kinetic parameters derived from triexponential NONLIN analysis showed that T1/2 alpha and T1/2 beta were 2 and 30 min respectively; no reliable estimate for T1/2 gamma could be obtained.,Acute i.v. Methadone Kinetics in Man: relationship to chronic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7171415/),min,30,232555,DB00333,Methadone
,7171415,clearance,The clearance was estimated as 149 /+- 62 and 163 /+- 49 ml min-1 in the 3- and 6-h studies respectively.,Acute i.v. Methadone Kinetics in Man: relationship to chronic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7171415/),[ml] / [min],149,232556,DB00333,Methadone
,7171415,clearance,The clearance was estimated as 149 /+- 62 and 163 /+- 49 ml min-1 in the 3- and 6-h studies respectively.,Acute i.v. Methadone Kinetics in Man: relationship to chronic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7171415/),[ml] / [min],163,232557,DB00333,Methadone
,16338275,trough (S)-methadone plasma levels,"CYP2B6 genotype influences (S)-methadone and, to a lesser extent, (R)-methadone plasma levels, with the median trough (S)-methadone plasma levels being 105, 122, and 209 ng . kg/mL . mg for the noncarriers of allele *6, heterozygous carriers, and homozygous carriers (*6/*6), respectively (P = .0004).","Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338275/),[kg·ng] / [mg·ml],105,232626,DB00333,Methadone
,16338275,trough (S)-methadone plasma levels,"CYP2B6 genotype influences (S)-methadone and, to a lesser extent, (R)-methadone plasma levels, with the median trough (S)-methadone plasma levels being 105, 122, and 209 ng . kg/mL . mg for the noncarriers of allele *6, heterozygous carriers, and homozygous carriers (*6/*6), respectively (P = .0004).","Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338275/),[kg·ng] / [mg·ml],122,232627,DB00333,Methadone
,16338275,trough (S)-methadone plasma levels,"CYP2B6 genotype influences (S)-methadone and, to a lesser extent, (R)-methadone plasma levels, with the median trough (S)-methadone plasma levels being 105, 122, and 209 ng . kg/mL . mg for the noncarriers of allele *6, heterozygous carriers, and homozygous carriers (*6/*6), respectively (P = .0004).","Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338275/),[kg·ng] / [mg·ml],209,232628,DB00333,Methadone
,16338275,trough plasma levels,"Lower peak and trough plasma levels of methadone and higher peak-to-trough ratios were measured in patients considered as nonresponders [median (R,S)-methadone trough plasma levels of 183 and 249 ng . kg/mL . mg (P = .0004) and median peak-to-trough ratios of 1.82 and 1.58 for high-dose nonresponders and high-dose responders, respectively (P = .0003)].","Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338275/),[kg·ng] / [mg·ml],183,232629,DB00333,Methadone
,16338275,trough plasma levels,"Lower peak and trough plasma levels of methadone and higher peak-to-trough ratios were measured in patients considered as nonresponders [median (R,S)-methadone trough plasma levels of 183 and 249 ng . kg/mL . mg (P = .0004) and median peak-to-trough ratios of 1.82 and 1.58 for high-dose nonresponders and high-dose responders, respectively (P = .0003)].","Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338275/),[kg·ng] / [mg·ml],249,232630,DB00333,Methadone
,16338275,peak-to-trough ratios,"Lower peak and trough plasma levels of methadone and higher peak-to-trough ratios were measured in patients considered as nonresponders [median (R,S)-methadone trough plasma levels of 183 and 249 ng . kg/mL . mg (P = .0004) and median peak-to-trough ratios of 1.82 and 1.58 for high-dose nonresponders and high-dose responders, respectively (P = .0003)].","Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338275/),,1.82,232631,DB00333,Methadone
,16338275,peak-to-trough ratios,"Lower peak and trough plasma levels of methadone and higher peak-to-trough ratios were measured in patients considered as nonresponders [median (R,S)-methadone trough plasma levels of 183 and 249 ng . kg/mL . mg (P = .0004) and median peak-to-trough ratios of 1.82 and 1.58 for high-dose nonresponders and high-dose responders, respectively (P = .0003)].","Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338275/),,1.58,232632,DB00333,Methadone
,9354306,oral clearance,The population mean oral clearance of methadone was 6.9+/-1.5 s.d. l h(-1) (5.3+/-1.2 s.d.,The pharmacokinetics of methadone in healthy subjects and opiate users. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),[l] / [h],6.9,233908,DB00333,Methadone
,9354306,oral clearance,The population mean oral clearance of methadone was 6.9+/-1.5 s.d. l h(-1) (5.3+/-1.2 s.d.,The pharmacokinetics of methadone in healthy subjects and opiate users. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),,5.3,233909,DB00333,Methadone
,9354306,clearance,"The former indicated a significantly lower clearance for opiate users (3.2+/-0.3 s.d. l h(-1), P<0.001); 95% CI for the difference = -3 to -6 l h(-1) and no difference in the population mean values of V/F (212+/-27 s.d. l and 239+/-121 s.d. l, P=0.15), while according to the latter analysis addiction was a covariate for V/F but not for oral clearance.",The pharmacokinetics of methadone in healthy subjects and opiate users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),,3.2,233910,DB00333,Methadone
,9354306,V/F,"The former indicated a significantly lower clearance for opiate users (3.2+/-0.3 s.d. l h(-1), P<0.001); 95% CI for the difference = -3 to -6 l h(-1) and no difference in the population mean values of V/F (212+/-27 s.d. l and 239+/-121 s.d. l, P=0.15), while according to the latter analysis addiction was a covariate for V/F but not for oral clearance.",The pharmacokinetics of methadone in healthy subjects and opiate users. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),d·l·s,212,233911,DB00333,Methadone
,9354306,V/F,"The former indicated a significantly lower clearance for opiate users (3.2+/-0.3 s.d. l h(-1), P<0.001); 95% CI for the difference = -3 to -6 l h(-1) and no difference in the population mean values of V/F (212+/-27 s.d. l and 239+/-121 s.d. l, P=0.15), while according to the latter analysis addiction was a covariate for V/F but not for oral clearance.",The pharmacokinetics of methadone in healthy subjects and opiate users. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),d·l·s,239,233912,DB00333,Methadone
,9354306,elimination half-life,The median elimination half-life of methadone in healthy subjects was 33-46 h depending on the method used to calculate this parameter.,The pharmacokinetics of methadone in healthy subjects and opiate users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),h,33-46,233913,DB00333,Methadone
,9354306,long terminal elimination half-life,"Estimates of the long terminal elimination half-life of methadone (33-46 h in healthy subjects and, possibly, longer in opiate users) indicated that accurate measurement of this parameter requires a duration of sampling longer than that used in this study.",The pharmacokinetics of methadone in healthy subjects and opiate users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),h,33-46,233914,DB00333,Methadone
,16175130,pH,"Saliva pH ranged from 5.1 to 7.6 (mean +/- SD, 6.7 +/- 0.5).",Can saliva replace plasma for the monitoring of methadone? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175130/),,6.7,234990,DB00333,Methadone
,16175130,saliva-to-plasma methadone,"Plasma and saliva concentrations correlated weakly [(RS)-, r = 0.14, P = 0.007, n = 44; (R)-, r = 0.10, P = 0.04, n = 43; (S)-, r = 0.22, P = 0.002, n = 43], and the mean saliva-to-plasma methadone concentration ratios were 1.1 (+/-1.3 SD), 1.5 (+/-1.5), and 0.8 (+/-0.8), for (RS)-, (R)-, and (S)-methadone, respectively.",Can saliva replace plasma for the monitoring of methadone? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175130/),,1.1,234991,DB00333,Methadone
,16175130,concentration ratios,"Plasma and saliva concentrations correlated weakly [(RS)-, r = 0.14, P = 0.007, n = 44; (R)-, r = 0.10, P = 0.04, n = 43; (S)-, r = 0.22, P = 0.002, n = 43], and the mean saliva-to-plasma methadone concentration ratios were 1.1 (+/-1.3 SD), 1.5 (+/-1.5), and 0.8 (+/-0.8), for (RS)-, (R)-, and (S)-methadone, respectively.",Can saliva replace plasma for the monitoring of methadone? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175130/),,1.1,234992,DB00333,Methadone
,16175130,concentration ratios,"Plasma and saliva concentrations correlated weakly [(RS)-, r = 0.14, P = 0.007, n = 44; (R)-, r = 0.10, P = 0.04, n = 43; (S)-, r = 0.22, P = 0.002, n = 43], and the mean saliva-to-plasma methadone concentration ratios were 1.1 (+/-1.3 SD), 1.5 (+/-1.5), and 0.8 (+/-0.8), for (RS)-, (R)-, and (S)-methadone, respectively.",Can saliva replace plasma for the monitoring of methadone? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175130/),,1.5,234993,DB00333,Methadone
,16175130,concentration ratios,"Plasma and saliva concentrations correlated weakly [(RS)-, r = 0.14, P = 0.007, n = 44; (R)-, r = 0.10, P = 0.04, n = 43; (S)-, r = 0.22, P = 0.002, n = 43], and the mean saliva-to-plasma methadone concentration ratios were 1.1 (+/-1.3 SD), 1.5 (+/-1.5), and 0.8 (+/-0.8), for (RS)-, (R)-, and (S)-methadone, respectively.",Can saliva replace plasma for the monitoring of methadone? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175130/),,0.8,234994,DB00333,Methadone
,16175130,unbound concentrations,"Corresponding values based on unbound concentrations of methadone in plasma were 21 (+/-20.6, n = 31), 21 (+/-19, n = 34), and 17 (+/-15, n = 36).",Can saliva replace plasma for the monitoring of methadone? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175130/),,21,234995,DB00333,Methadone
,16175130,unbound concentrations,"Corresponding values based on unbound concentrations of methadone in plasma were 21 (+/-20.6, n = 31), 21 (+/-19, n = 34), and 17 (+/-15, n = 36).",Can saliva replace plasma for the monitoring of methadone? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175130/),,21,234996,DB00333,Methadone
,16175130,unbound concentrations,"Corresponding values based on unbound concentrations of methadone in plasma were 21 (+/-20.6, n = 31), 21 (+/-19, n = 34), and 17 (+/-15, n = 36).",Can saliva replace plasma for the monitoring of methadone? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175130/),,17,234997,DB00333,Methadone
,20017819,plasma concentration,"After IV administration, the plasma concentration of methadone at 10 minutes was 82.1 +/- 9.2 ng mL(-1) (mean +/- SD), the terminal half-life was 3.9 +/- 1.0 hours, the volume of distribution 9.2 +/- 3.3 L kg(-1) and plasma clearance 27.9 +/- 7.6 mL minute(-1) kg(-1).",Clinical pharmacology of methadone in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),[ng] / [ml],82.1,236919,DB00333,Methadone
,20017819,terminal half-life,"After IV administration, the plasma concentration of methadone at 10 minutes was 82.1 +/- 9.2 ng mL(-1) (mean +/- SD), the terminal half-life was 3.9 +/- 1.0 hours, the volume of distribution 9.2 +/- 3.3 L kg(-1) and plasma clearance 27.9 +/- 7.6 mL minute(-1) kg(-1).",Clinical pharmacology of methadone in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),h,3.9,236920,DB00333,Methadone
,20017819,volume of distribution,"After IV administration, the plasma concentration of methadone at 10 minutes was 82.1 +/- 9.2 ng mL(-1) (mean +/- SD), the terminal half-life was 3.9 +/- 1.0 hours, the volume of distribution 9.2 +/- 3.3 L kg(-1) and plasma clearance 27.9 +/- 7.6 mL minute(-1) kg(-1).",Clinical pharmacology of methadone in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),[l] / [kg],9.2,236921,DB00333,Methadone
,20017819,plasma clearance,"After IV administration, the plasma concentration of methadone at 10 minutes was 82.1 +/- 9.2 ng mL(-1) (mean +/- SD), the terminal half-life was 3.9 +/- 1.0 hours, the volume of distribution 9.2 +/- 3.3 L kg(-1) and plasma clearance 27.9 +/- 7.6 mL minute(-1) kg(-1).",Clinical pharmacology of methadone in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),[ml] / [kg·minute],27.9,236922,DB00333,Methadone
,20017819,time to maximal plasma concentration,"After SC administration, time to maximal plasma concentration was 1.26 +/- 1.04 hours and maximal plasma concentration of methadone was 23.9 +/- 14.4 ng mL(-1), the terminal half-life was 10.7 +/- 4.3 hours and bioavailability was 79 +/- 22%.",Clinical pharmacology of methadone in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),h,1.26,236923,DB00333,Methadone
,20017819,maximal plasma concentration,"After SC administration, time to maximal plasma concentration was 1.26 +/- 1.04 hours and maximal plasma concentration of methadone was 23.9 +/- 14.4 ng mL(-1), the terminal half-life was 10.7 +/- 4.3 hours and bioavailability was 79 +/- 22%.",Clinical pharmacology of methadone in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),[ng] / [ml],23.9,236924,DB00333,Methadone
,20017819,terminal half-life,"After SC administration, time to maximal plasma concentration was 1.26 +/- 1.04 hours and maximal plasma concentration of methadone was 23.9 +/- 14.4 ng mL(-1), the terminal half-life was 10.7 +/- 4.3 hours and bioavailability was 79 +/- 22%.",Clinical pharmacology of methadone in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),h,10.7,236925,DB00333,Methadone
,20017819,bioavailability,"After SC administration, time to maximal plasma concentration was 1.26 +/- 1.04 hours and maximal plasma concentration of methadone was 23.9 +/- 14.4 ng mL(-1), the terminal half-life was 10.7 +/- 4.3 hours and bioavailability was 79 +/- 22%.",Clinical pharmacology of methadone in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),%,79,236926,DB00333,Methadone
,9812178,t1/2 beta,The clinically relevant t1/2 beta is about 3 to 5 hours.,Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812178/),h,3 to 5,239662,DB00333,Methadone
,9812178,apparent oral clearance,"The pharmacokinetics of ritonavir are relatively linear after multiple doses, with apparent oral clearance averaging 7 to 9 L/h.",Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812178/),[l] / [h],7 to 9,239663,DB00333,Methadone
,24080665,area under the concentration-time curve to the end of the dosing period (AUCtau),"Compared to baseline values, the R-methadone mean area under the concentration-time curve to the end of the dosing period (AUCtau) (5,550 versus 6,210 h · ng/ml) and mean maximum concentration of drug in serum (Cmax) (316 versus 337 ng/ml) did not significantly increase in the presence of EVG/COBI.",Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080665/),[h·ng] / [ml],"5,550",240381,DB00333,Methadone
,24080665,area under the concentration-time curve to the end of the dosing period (AUCtau),"Compared to baseline values, the R-methadone mean area under the concentration-time curve to the end of the dosing period (AUCtau) (5,550 versus 6,210 h · ng/ml) and mean maximum concentration of drug in serum (Cmax) (316 versus 337 ng/ml) did not significantly increase in the presence of EVG/COBI.",Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080665/),[h·ng] / [ml],"6,210",240382,DB00333,Methadone
,24080665,maximum concentration of drug in serum (Cmax),"Compared to baseline values, the R-methadone mean area under the concentration-time curve to the end of the dosing period (AUCtau) (5,550 versus 6,210 h · ng/ml) and mean maximum concentration of drug in serum (Cmax) (316 versus 337 ng/ml) did not significantly increase in the presence of EVG/COBI.",Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080665/),[ng] / [ml],316,240383,DB00333,Methadone
,24080665,maximum concentration of drug in serum (Cmax),"Compared to baseline values, the R-methadone mean area under the concentration-time curve to the end of the dosing period (AUCtau) (5,550 versus 6,210 h · ng/ml) and mean maximum concentration of drug in serum (Cmax) (316 versus 337 ng/ml) did not significantly increase in the presence of EVG/COBI.",Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080665/),[ng] / [ml],337,240384,DB00333,Methadone
,24080665,AUCtau,"Compared to baseline values, the S-methadone mean AUCtau (7,040 versus 7,540 h · ng/ml) and mean Cmax (446 versus 452 ng/ml) did not significantly increase in the presence of EVG/COBI.",Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080665/),[h·ng] / [ml],"7,040",240385,DB00333,Methadone
,24080665,AUCtau,"Compared to baseline values, the S-methadone mean AUCtau (7,040 versus 7,540 h · ng/ml) and mean Cmax (446 versus 452 ng/ml) did not significantly increase in the presence of EVG/COBI.",Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080665/),[h·ng] / [ml],"7,540",240386,DB00333,Methadone
,24080665,Cmax,"Compared to baseline values, the S-methadone mean AUCtau (7,040 versus 7,540 h · ng/ml) and mean Cmax (446 versus 452 ng/ml) did not significantly increase in the presence of EVG/COBI.",Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080665/),[ng] / [ml],446,240387,DB00333,Methadone
,24080665,Cmax,"Compared to baseline values, the S-methadone mean AUCtau (7,040 versus 7,540 h · ng/ml) and mean Cmax (446 versus 452 ng/ml) did not significantly increase in the presence of EVG/COBI.",Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080665/),[ng] / [ml],452,240388,DB00333,Methadone
,7894677,R/S ratio,The mean R/S ratio of the plasma concentrations was 0.80 +/- 0.05 (n = 3 samples) in one patient taking 25-27.5 mg daily and 1.21 +/- 0.12 (n = 6 samples) in another taking 10-20 mg daily.,Sensitive high-performance liquid chromatographic assay with ultraviolet detection of methadone enantiomers in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894677/),,0.80,240969,DB00333,Methadone
,7894677,R/S ratio,The mean R/S ratio of the plasma concentrations was 0.80 +/- 0.05 (n = 3 samples) in one patient taking 25-27.5 mg daily and 1.21 +/- 0.12 (n = 6 samples) in another taking 10-20 mg daily.,Sensitive high-performance liquid chromatographic assay with ultraviolet detection of methadone enantiomers in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894677/),,1.21,240970,DB00333,Methadone
,3528988,Terminal half-lives,Terminal half-lives (mean +/- S.D.) were 30.4 +/- 16.3 h and 2.7 +/- 1.2 h respectively for methadone and morphine while the clearance values (mean +/- S.D.) were 0.19 +/- 0.13 l/min and 1.16 +/- 0.47 l/min.,A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528988/),h,30.4,241267,DB00333,Methadone
,3528988,Terminal half-lives,Terminal half-lives (mean +/- S.D.) were 30.4 +/- 16.3 h and 2.7 +/- 1.2 h respectively for methadone and morphine while the clearance values (mean +/- S.D.) were 0.19 +/- 0.13 l/min and 1.16 +/- 0.47 l/min.,A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528988/),h,2.7,241268,DB00333,Methadone
,3528988,clearance,Terminal half-lives (mean +/- S.D.) were 30.4 +/- 16.3 h and 2.7 +/- 1.2 h respectively for methadone and morphine while the clearance values (mean +/- S.D.) were 0.19 +/- 0.13 l/min and 1.16 +/- 0.47 l/min.,A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528988/),[l] / [min],0.19,241269,DB00333,Methadone
,3528988,clearance,Terminal half-lives (mean +/- S.D.) were 30.4 +/- 16.3 h and 2.7 +/- 1.2 h respectively for methadone and morphine while the clearance values (mean +/- S.D.) were 0.19 +/- 0.13 l/min and 1.16 +/- 0.47 l/min.,A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528988/),[l] / [min],1.16,241270,DB00333,Methadone
,3528988,oral bioavailability,"There were pronounced differences in oral bioavailability between the two opioids: methadone, 79 +/- 11.7%, compared to morphine, 26 +/- 13% (mean +/- S.D.).",A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528988/),%,79,241271,DB00333,Methadone
,3528988,oral bioavailability,"There were pronounced differences in oral bioavailability between the two opioids: methadone, 79 +/- 11.7%, compared to morphine, 26 +/- 13% (mean +/- S.D.).",A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528988/),%,26,241272,DB00333,Methadone
,24236993,pKa,"It has been argued that absorption of buprenorphine through the buccal mucosa is high, in part due to its pKa of 8.24.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),,8.24,243813,DB00333,Methadone
,24236993,pKa,"Morphine, methadone, hydromorphone, and oxymorphone have a pKa between 8 and 9.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),,8 and 9,243814,DB00333,Methadone
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,36.6,243815,DB00333,Methadone
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,44.2,243816,DB00333,Methadone
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,22.4,243817,DB00333,Methadone
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,18.8,243818,DB00333,Methadone
,31197847,Cmax,"The results showed reduced and delayed absorption of both dexmedetomidine and methadone when administered through an oral transmucosal route, with median (range) Cmax values of 0.82 (0.42-1.49) ng/ml and 13.22 (2.80-52.30) ng/ml, respectively.",Clinical pharmacokinetics of a dexmedetomidine-methadone combination in dogs undergoing routine anaesthesia after buccal or intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31197847/),[ng] / [ml],0.82,243942,DB00333,Methadone
,31197847,Cmax,"The results showed reduced and delayed absorption of both dexmedetomidine and methadone when administered through an oral transmucosal route, with median (range) Cmax values of 0.82 (0.42-1.49) ng/ml and 13.22 (2.80-52.30) ng/ml, respectively.",Clinical pharmacokinetics of a dexmedetomidine-methadone combination in dogs undergoing routine anaesthesia after buccal or intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31197847/),[ng] / [ml],13.22,243943,DB00333,Methadone
,31197847,relative bioavailability,The relative bioavailability was low: 16.34% (dexmedetomidine) and 15.5% (methadone).,Clinical pharmacokinetics of a dexmedetomidine-methadone combination in dogs undergoing routine anaesthesia after buccal or intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31197847/),%,16.34,243944,DB00333,Methadone
,31197847,relative bioavailability,The relative bioavailability was low: 16.34% (dexmedetomidine) and 15.5% (methadone).,Clinical pharmacokinetics of a dexmedetomidine-methadone combination in dogs undergoing routine anaesthesia after buccal or intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31197847/),%,15.5,243945,DB00333,Methadone
,33629899,volumes of distribution,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg],692,244692,DB00333,Methadone
,33629899,volumes of distribution,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg],"2,439",244693,DB00333,Methadone
,33629899,volumes of distribution,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg],"2,293",244694,DB00333,Methadone
,33629899,metabolic clearance,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg·min],23.3,244695,DB00333,Methadone
,33629899,first,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg·min],556.4,244696,DB00333,Methadone
,33629899,second,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg·min],556.4,244697,DB00333,Methadone
,33629899,distributional clearances,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg·min],556.4,244698,DB00333,Methadone
,33629899,distributional clearances,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg·min],51.8,244699,DB00333,Methadone
,33629899,bioavailability,Typical bioavailability after IM administration was 79%.,Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),%,79,244700,DB00333,Methadone
,33629899,Elimination half-life,"Elimination half-life was 177 minutes, and maximum plasma concentration after IM administration was 950 ng/mL.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),min,177,244701,DB00333,Methadone
,33629899,maximum plasma concentration,"Elimination half-life was 177 minutes, and maximum plasma concentration after IM administration was 950 ng/mL.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ng] / [ml],950,244702,DB00333,Methadone
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,20,245762,DB00333,Methadone
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,6,245763,DB00333,Methadone
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,2 to 3,245764,DB00333,Methadone
,13957,half-life,The half-life of methadone averages 25 hours.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,25,245765,DB00333,Methadone
,13957,half-life,Naloxone rapidly disappears from the serum in man and the initial distribution phase has a half-life of 4 minutes.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,4,245766,DB00333,Methadone
,13957,half-life,The half-life of naloxone in serum following distribution is 64 minutes.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,64,245767,DB00333,Methadone
,10584978,total,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],43.0,247040,DB00333,Methadone
,10584978,clearance,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],43.0,247041,DB00333,Methadone
,10584978,clearance,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],51.0,247042,DB00333,Methadone
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],7.11,247043,DB00333,Methadone
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],8.60,247044,DB00333,Methadone
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],11.5,247045,DB00333,Methadone
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],14.0,247046,DB00333,Methadone
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],4.05,247047,DB00333,Methadone
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],4.94,247048,DB00333,Methadone
,10584978,half-life,Antipyrine half-life was significantly reduced (12.3 +/- 2.8 h to 9.4 +/- 2.2 h) and some patients developed clinical signs of L-methadone underdosage.,Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),h,12.3,247049,DB00333,Methadone
,10584978,half-life,Antipyrine half-life was significantly reduced (12.3 +/- 2.8 h to 9.4 +/- 2.2 h) and some patients developed clinical signs of L-methadone underdosage.,Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),h,9.4,247050,DB00333,Methadone
,26404026,TT,"Results TT and MT increased above baseline from 20-240 mins and 5-40 mins, respectively, after intramuscular (IM) administration ( P <0.005).",Effect of intramuscular methadone on pharmacokinetic data and thermal and mechanical nociceptive thresholds in the cat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26404026/),min,20-240,250466,DB00333,Methadone
,26404026,MT,"Results TT and MT increased above baseline from 20-240 mins and 5-40 mins, respectively, after intramuscular (IM) administration ( P <0.005).",Effect of intramuscular methadone on pharmacokinetic data and thermal and mechanical nociceptive thresholds in the cat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26404026/),min,5-40,250467,DB00333,Methadone
,26404026,maximum delta T,Mean maximum delta T (measured as TT minus baseline threshold) was 7.9°C (95% confidence interval [CI] 4.3-11.6) at 60 mins and mean maximum delta F (measured as MT minus baseline threshold) was 4.2 (95% CI 1.6-6.7) N at 45 mins.,Effect of intramuscular methadone on pharmacokinetic data and thermal and mechanical nociceptive thresholds in the cat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26404026/),°c,7.9,250468,DB00333,Methadone
,26404026,maximum delta F,Mean maximum delta T (measured as TT minus baseline threshold) was 7.9°C (95% confidence interval [CI] 4.3-11.6) at 60 mins and mean maximum delta F (measured as MT minus baseline threshold) was 4.2 (95% CI 1.6-6.7) N at 45 mins.,Effect of intramuscular methadone on pharmacokinetic data and thermal and mechanical nociceptive thresholds in the cat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26404026/),n,4.2,250469,DB00333,Methadone
,26404026,clearance,"IM methadone concentration-time data decreased curvilinearly, and gave a clearance estimate of mean 9.1 ml/kg/min (range 5.2-15.7) with median Tmax at 20 mins (range 5-360 mins).",Effect of intramuscular methadone on pharmacokinetic data and thermal and mechanical nociceptive thresholds in the cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26404026/),[ml] / [kg·min],9.1,250470,DB00333,Methadone
,26404026,Tmax,"IM methadone concentration-time data decreased curvilinearly, and gave a clearance estimate of mean 9.1 ml/kg/min (range 5.2-15.7) with median Tmax at 20 mins (range 5-360 mins).",Effect of intramuscular methadone on pharmacokinetic data and thermal and mechanical nociceptive thresholds in the cat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26404026/),min,20,250471,DB00333,Methadone
,7632750,EC90,"Results demonstrate a S-shaped, 24 hr trough plasma methadone concentration response curve with effective concentrations, EC90 = 80 micrograms/L, EC98 = 600 micrograms/L.",Utilization of plasma and urine methadone concentration measurements to limit narcotics use in methadone maintenance patients: II. Generation of plasma concentration response curves. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7632750/),[μg] / [l],80,250744,DB00333,Methadone
,7632750,EC98,"Results demonstrate a S-shaped, 24 hr trough plasma methadone concentration response curve with effective concentrations, EC90 = 80 micrograms/L, EC98 = 600 micrograms/L.",Utilization of plasma and urine methadone concentration measurements to limit narcotics use in methadone maintenance patients: II. Generation of plasma concentration response curves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7632750/),[μg] / [l],600,250745,DB00333,Methadone
,3514045,oral bioavailability,The oral bioavailability is approximately 40% with marked patient-to-patient variations as a result of differences in presystemic elimination.,High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514045/),%,40,251886,DB00333,Methadone
,3514045,volume of distribution,The reported values for the volume of distribution range from 1.0 to 4.7 L/kg.,High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514045/),[l] / [kg],1.0 to 4.7,251887,DB00333,Methadone
,3514045,Plasma protein binding,Plasma protein binding is about 30%.,High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514045/),%,30,251888,DB00333,Methadone
,3514045,elimination half-life,The elimination half-life varies between 0.7 and 7.8 hours.,High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514045/),h,0.7 and 7.8,251889,DB00333,Methadone
,3514045,Plasma clearance,Plasma clearance is approximately 19 ml/min/kg (5 to 34 ml/min/kg) and mostly accounted for by metabolic clearance.,High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514045/),[ml] / [kg·min],19,251890,DB00333,Methadone
,24962270,elimination clearance,"Population parameter estimates of methadone were elimination clearance (17.3 L hour(-1) ), metabolic clearance (34.6 L hour(-1) ), volume of distribution of compartment 1 (216.0 L) and volume of distribution of compartment 2 (384.0 L).",Population pharmacokinetics of methadone hydrochloride after a single intramuscular administration in adult Japanese sika deer (Cervus nippon nippon). ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962270/),[l] / [hour],17.3,252054,DB00333,Methadone
,24962270,metabolic clearance,"Population parameter estimates of methadone were elimination clearance (17.3 L hour(-1) ), metabolic clearance (34.6 L hour(-1) ), volume of distribution of compartment 1 (216.0 L) and volume of distribution of compartment 2 (384.0 L).",Population pharmacokinetics of methadone hydrochloride after a single intramuscular administration in adult Japanese sika deer (Cervus nippon nippon). ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962270/),[l] / [hour],34.6,252055,DB00333,Methadone
,24962270,volume of distribution of compartment 1,"Population parameter estimates of methadone were elimination clearance (17.3 L hour(-1) ), metabolic clearance (34.6 L hour(-1) ), volume of distribution of compartment 1 (216.0 L) and volume of distribution of compartment 2 (384.0 L).",Population pharmacokinetics of methadone hydrochloride after a single intramuscular administration in adult Japanese sika deer (Cervus nippon nippon). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962270/),l,216.0,252056,DB00333,Methadone
,24962270,volume of distribution of compartment 2,"Population parameter estimates of methadone were elimination clearance (17.3 L hour(-1) ), metabolic clearance (34.6 L hour(-1) ), volume of distribution of compartment 1 (216.0 L) and volume of distribution of compartment 2 (384.0 L).",Population pharmacokinetics of methadone hydrochloride after a single intramuscular administration in adult Japanese sika deer (Cervus nippon nippon). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962270/),l,384.0,252057,DB00333,Methadone
,24962270,elimination clearance,"Population parameter estimates of EDDP were elimination clearance (121.0 L hour(-1) ), volume of distribution of compartment 3 (1.08 L) and volume of distribution of compartment 4 (499.5 L).",Population pharmacokinetics of methadone hydrochloride after a single intramuscular administration in adult Japanese sika deer (Cervus nippon nippon). ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962270/),[l] / [hour],121.0,252058,DB00333,Methadone
,24962270,volume of distribution of compartment 3,"Population parameter estimates of EDDP were elimination clearance (121.0 L hour(-1) ), volume of distribution of compartment 3 (1.08 L) and volume of distribution of compartment 4 (499.5 L).",Population pharmacokinetics of methadone hydrochloride after a single intramuscular administration in adult Japanese sika deer (Cervus nippon nippon). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962270/),l,1.08,252059,DB00333,Methadone
,24962270,volume of distribution of compartment 4,"Population parameter estimates of EDDP were elimination clearance (121.0 L hour(-1) ), volume of distribution of compartment 3 (1.08 L) and volume of distribution of compartment 4 (499.5 L).",Population pharmacokinetics of methadone hydrochloride after a single intramuscular administration in adult Japanese sika deer (Cervus nippon nippon). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962270/),l,499.5,252060,DB00333,Methadone
,24962270,total clearance,"The total clearance and total volume of distribution of methadone and EDDP were 51.9 L hour(-1) , 121.0 L hour (-1) , 600.0 L and 500.6 L, respectively.",Population pharmacokinetics of methadone hydrochloride after a single intramuscular administration in adult Japanese sika deer (Cervus nippon nippon). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962270/),[l] / [hour],51.9,252061,DB00333,Methadone
,24962270,total volume of distribution,"The total clearance and total volume of distribution of methadone and EDDP were 51.9 L hour(-1) , 121.0 L hour (-1) , 600.0 L and 500.6 L, respectively.",Population pharmacokinetics of methadone hydrochloride after a single intramuscular administration in adult Japanese sika deer (Cervus nippon nippon). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962270/),l,500.6,252062,DB00333,Methadone
,24962270,terminal elimination half-life,The methadone terminal elimination half-life was 8.19 hours.,Population pharmacokinetics of methadone hydrochloride after a single intramuscular administration in adult Japanese sika deer (Cervus nippon nippon). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962270/),h,8.19,252063,DB00333,Methadone
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,97.87,254797,DB00333,Methadone
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,96.74,254798,DB00333,Methadone
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,78.9,254799,DB00333,Methadone
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,86.97,254800,DB00333,Methadone
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,96.46,254801,DB00333,Methadone
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,53.11,254802,DB00333,Methadone
,30370647,IC50,"And the IC50 for inhibition activity of isavuconazole, ketoconazole, and voriconazole in rat microsomes were 7.76 μM, 8.33 μM, and 4.45 μM, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),μM,7.76,254803,DB00333,Methadone
,30370647,IC50,"And the IC50 for inhibition activity of isavuconazole, ketoconazole, and voriconazole in rat microsomes were 7.76 μM, 8.33 μM, and 4.45 μM, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),μM,8.33,254804,DB00333,Methadone
,30370647,IC50,"And the IC50 for inhibition activity of isavuconazole, ketoconazole, and voriconazole in rat microsomes were 7.76 μM, 8.33 μM, and 4.45 μM, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),μM,4.45,254805,DB00333,Methadone
,32700999,maximum observed concentration,"Geometric mean maximum observed concentration of methadone in plasma was 35.1 and 33.5 ng/mL and geometric mean terminal half-life was 7.92 and 7.09 hours after methadone-fluconazole and methadone-fluconazole-naltrexone treatment, respectively.",Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700999/),[ng] / [ml],35.1,258336,DB00333,Methadone
,32700999,maximum observed concentration,"Geometric mean maximum observed concentration of methadone in plasma was 35.1 and 33.5 ng/mL and geometric mean terminal half-life was 7.92 and 7.09 hours after methadone-fluconazole and methadone-fluconazole-naltrexone treatment, respectively.",Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700999/),[ng] / [ml],33.5,258337,DB00333,Methadone
,32700999,terminal half-life,"Geometric mean maximum observed concentration of methadone in plasma was 35.1 and 33.5 ng/mL and geometric mean terminal half-life was 7.92 and 7.09 hours after methadone-fluconazole and methadone-fluconazole-naltrexone treatment, respectively.",Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700999/),h,7.92,258338,DB00333,Methadone
,32700999,terminal half-life,"Geometric mean maximum observed concentration of methadone in plasma was 35.1 and 33.5 ng/mL and geometric mean terminal half-life was 7.92 and 7.09 hours after methadone-fluconazole and methadone-fluconazole-naltrexone treatment, respectively.",Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700999/),h,7.09,258339,DB00333,Methadone
,26368295,tissue store,The tissue store measured 13-17 mg.,Methadone Recycling Sustains Drug Reservoir in Tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26368295/),mg,13-17,258522,DB00333,Methadone
,26368295,rate of accumulation,We estimate the rate of accumulation (or storage) of methadone in tissue was 0.029-7.29 mg/h.,Methadone Recycling Sustains Drug Reservoir in Tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26368295/),[mg] / [h],0.029-7.29,258523,DB00333,Methadone
,26368295,storage,We estimate the rate of accumulation (or storage) of methadone in tissue was 0.029-7.29 mg/h.,Methadone Recycling Sustains Drug Reservoir in Tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26368295/),[mg] / [h],0.029-7.29,258524,DB00333,Methadone
,25072223,Peak miosis,"Peak miosis was similar in controls and cyclosporine-treated subjects after oral methadone (1.4±0.4 and 1.3±0.5 mm/mg, respectively) and IV methadone (3.1±1.0 and 3.2±0.8 mm, respectively).",Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25072223/),[mm] / [mg],1.4,258605,DB00333,Methadone
,25072223,Peak miosis,"Peak miosis was similar in controls and cyclosporine-treated subjects after oral methadone (1.4±0.4 and 1.3±0.5 mm/mg, respectively) and IV methadone (3.1±1.0 and 3.2±0.8 mm, respectively).",Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25072223/),[mm] / [mg],1.3,258606,DB00333,Methadone
,25072223,Peak miosis,"Peak miosis was similar in controls and cyclosporine-treated subjects after oral methadone (1.4±0.4 and 1.3±0.5 mm/mg, respectively) and IV methadone (3.1±1.0 and 3.2±0.8 mm, respectively).",Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25072223/),mm,3.1,258607,DB00333,Methadone
,25072223,Peak miosis,"Peak miosis was similar in controls and cyclosporine-treated subjects after oral methadone (1.4±0.4 and 1.3±0.5 mm/mg, respectively) and IV methadone (3.1±1.0 and 3.2±0.8 mm, respectively).",Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25072223/),mm,3.2,258608,DB00333,Methadone
,25397548,CT/HDL ratio,CT/HDL ratio decreases from 4.35 to 4.28 after six months.,A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25397548/),,4.35,259566,DB00333,Methadone
,25397548,CT/HDL ratio,CT/HDL ratio decreases from 4.35 to 4.28 after six months.,A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25397548/),,4.28,259567,DB00333,Methadone
,25397548,plasma trough level,"Geometric mean plasma trough level of RAL was 166 ng/mL (IQR, 40-249) and only one patient (6%) was below the in vitro IC50 of the wild type.",A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25397548/),[ng] / [ml],166,259568,DB00333,Methadone
,837634,half-life of drug in blood,"The mean half-life of drug in blood was 22 hr for racemic methadone, 24 hr for l-methadone, and 25 hr for d-methadone.",Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837634/),h,22,261135,DB00333,Methadone
,837634,half-life of drug in blood,"The mean half-life of drug in blood was 22 hr for racemic methadone, 24 hr for l-methadone, and 25 hr for d-methadone.",Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837634/),h,24,261136,DB00333,Methadone
,837634,half-life of drug in blood,"The mean half-life of drug in blood was 22 hr for racemic methadone, 24 hr for l-methadone, and 25 hr for d-methadone.",Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837634/),h,25,261137,DB00333,Methadone
,837634,potency ratio,"The potency ratio of l-methadone to d,l-methdone, calculated from blood drug concentration data, was found to be 3.0 for respiratory depression and 2.7 for miosis.",Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837634/),,3.0,261138,DB00333,Methadone
,837634,potency ratio,"The potency ratio of l-methadone to d,l-methdone, calculated from blood drug concentration data, was found to be 3.0 for respiratory depression and 2.7 for miosis.",Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837634/),,2.7,261139,DB00333,Methadone
,20236544,Cmin,"The median SQV Cmin (n = 49) was 295 ng/ml (range, 53-2172).","Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20236544/),[ng] / [ml],295,264710,DB00333,Methadone
,10984743,R(s),"Methadone enantiomers and EDDP, the main metabolite of methadone, were separated (R(s) = 2.0 for methadone enantiomers) following liquid-liquid extraction from human serum and urine followed by reverse-phase high-performance liquid chromatography on a derivatized beta-cyclodextrin column and quantified at therapeutic concentrations with ultraviolet detection.",Development and application of a chiral high performance liquid chromatography assay for pharmacokinetic studies of methadone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984743/),,2.0,266598,DB00333,Methadone
,10984743,free fraction,"The binding of methadone to plasma proteins was enantioselective with the active (-)-(R) enantiomer having the highest free fraction (mean +/- SD: 21.2+/-7.6% vs. 13.3+/-6.2% for (+)-(S)-methadone, n = 8).",Development and application of a chiral high performance liquid chromatography assay for pharmacokinetic studies of methadone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984743/),%,21.2,266599,DB00333,Methadone
,10984743,free fraction,"The binding of methadone to plasma proteins was enantioselective with the active (-)-(R) enantiomer having the highest free fraction (mean +/- SD: 21.2+/-7.6% vs. 13.3+/-6.2% for (+)-(S)-methadone, n = 8).",Development and application of a chiral high performance liquid chromatography assay for pharmacokinetic studies of methadone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984743/),%,13.3,266600,DB00333,Methadone
,10984743,Binding,"Binding of methadone to erythrocytes was not apparently enantioselective (38.6+/-1.3% and 38.1+/-1.4% bound for (-)-(R)- and (+)-(S)-methadone, respectively).",Development and application of a chiral high performance liquid chromatography assay for pharmacokinetic studies of methadone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984743/),%,38.6,266601,DB00333,Methadone
,10984743,Binding,"Binding of methadone to erythrocytes was not apparently enantioselective (38.6+/-1.3% and 38.1+/-1.4% bound for (-)-(R)- and (+)-(S)-methadone, respectively).",Development and application of a chiral high performance liquid chromatography assay for pharmacokinetic studies of methadone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984743/),%,38.1,266602,DB00333,Methadone
,21862022,LODs,"The LODs were 200 pg/mL for MET and EMDP, and 400 pg/mL for EDDP.",Cation-selective exhaustive injection and sweeping micellar electrokinetic chromatography for the analysis of methadone and its metabolites in serum of heroin addicts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21862022/),[pg] / [ml],200,267439,DB00333,Methadone
,21862022,LODs,"The LODs were 200 pg/mL for MET and EMDP, and 400 pg/mL for EDDP.",Cation-selective exhaustive injection and sweeping micellar electrokinetic chromatography for the analysis of methadone and its metabolites in serum of heroin addicts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21862022/),[pg] / [ml],400,267440,DB00333,Methadone
,23973378,plasma clearance,"The mean plasma clearance of methadone was 19.9 ± 8.5 mL/min (± SD) compared with 105.7 ± 8.3 mL/min for HM, a difference of 85.7 mL/min (95% confidence interval 61.9 to 109.1).",Intradialytic clearance of opioids: methadone versus hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23973378/),[ml] / [min],19.9,271827,DB00333,Methadone
,23973378,plasma clearance,"The mean plasma clearance of methadone was 19.9 ± 8.5 mL/min (± SD) compared with 105.7 ± 8.3 mL/min for HM, a difference of 85.7 mL/min (95% confidence interval 61.9 to 109.1).",Intradialytic clearance of opioids: methadone versus hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23973378/),[ml] / [min],105.7,271828,DB00333,Methadone
,12115824,k(01),"RS-Methadone rate of absorption (mean +/- SE) was faster in OP(oral) (k(01) = 0.31 +/- 0.04 min(-1)) than in CO(oral) (k(01) = 0.05 +/- 0.007 min(-1)), consequently plasma peak concentrations (C(max)) were greater (197.41 +/- 33.70 ng/mL versus 83.54 +/- 7.97 ng/mL) and the time to reach C(max) (t(max)) was shorter (11.23 +/- 1.32 min versus 39.18 +/- 1.74 min).",Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),1/[min],0.31,272820,DB00333,Methadone
,12115824,k(01),"RS-Methadone rate of absorption (mean +/- SE) was faster in OP(oral) (k(01) = 0.31 +/- 0.04 min(-1)) than in CO(oral) (k(01) = 0.05 +/- 0.007 min(-1)), consequently plasma peak concentrations (C(max)) were greater (197.41 +/- 33.70 ng/mL versus 83.54 +/- 7.97 ng/mL) and the time to reach C(max) (t(max)) was shorter (11.23 +/- 1.32 min versus 39.18 +/- 1.74 min).",Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),1/[min],0.05,272821,DB00333,Methadone
,12115824,plasma peak concentrations (C(max)),"RS-Methadone rate of absorption (mean +/- SE) was faster in OP(oral) (k(01) = 0.31 +/- 0.04 min(-1)) than in CO(oral) (k(01) = 0.05 +/- 0.007 min(-1)), consequently plasma peak concentrations (C(max)) were greater (197.41 +/- 33.70 ng/mL versus 83.54 +/- 7.97 ng/mL) and the time to reach C(max) (t(max)) was shorter (11.23 +/- 1.32 min versus 39.18 +/- 1.74 min).",Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),[ng] / [ml],197.41,272822,DB00333,Methadone
,12115824,plasma peak concentrations (C(max)),"RS-Methadone rate of absorption (mean +/- SE) was faster in OP(oral) (k(01) = 0.31 +/- 0.04 min(-1)) than in CO(oral) (k(01) = 0.05 +/- 0.007 min(-1)), consequently plasma peak concentrations (C(max)) were greater (197.41 +/- 33.70 ng/mL versus 83.54 +/- 7.97 ng/mL) and the time to reach C(max) (t(max)) was shorter (11.23 +/- 1.32 min versus 39.18 +/- 1.74 min).",Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),[ng] / [ml],83.54,272823,DB00333,Methadone
,12115824,time to reach C(max) (t(max)),"RS-Methadone rate of absorption (mean +/- SE) was faster in OP(oral) (k(01) = 0.31 +/- 0.04 min(-1)) than in CO(oral) (k(01) = 0.05 +/- 0.007 min(-1)), consequently plasma peak concentrations (C(max)) were greater (197.41 +/- 33.70 ng/mL versus 83.54 +/- 7.97 ng/mL) and the time to reach C(max) (t(max)) was shorter (11.23 +/- 1.32 min versus 39.18 +/- 1.74 min).",Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),min,11.23,272824,DB00333,Methadone
,12115824,time to reach C(max) (t(max)),"RS-Methadone rate of absorption (mean +/- SE) was faster in OP(oral) (k(01) = 0.31 +/- 0.04 min(-1)) than in CO(oral) (k(01) = 0.05 +/- 0.007 min(-1)), consequently plasma peak concentrations (C(max)) were greater (197.41 +/- 33.70 ng/mL versus 83.54 +/- 7.97 ng/mL) and the time to reach C(max) (t(max)) was shorter (11.23 +/- 1.32 min versus 39.18 +/- 1.74 min).",Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),min,39.18,272825,DB00333,Methadone
,12115824,k(e0),The relationship between Cp and drug effect in the OP(oral) group showed a counterclockwise hysteresis (k(e0) of 0.018 +/- 0.006 min(-1)).,Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),1/[min],0.018,272826,DB00333,Methadone
